The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Transplantation of an individual's own tissue from one site to another site.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
The transference of a part of or an entire liver from one human or animal to another.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Progenitor cells from which all blood cells derive.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
The transference of a kidney from one human or animal to another.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
The return of a sign, symptom, or disease after a remission.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An organism whose body contains cell populations of different genotypes as a result of the TRANSPLANTATION of donor cells after sufficient ionizing radiation to destroy the mature recipient's cells which would otherwise reject the donor cells.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Removal of bone marrow and evaluation of its histologic picture.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
Elements of limited time intervals, contributing to particular results or situations.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The transference of a heart from one human or animal to another.
Disease having a short and relatively severe course.
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
An individual that contains cell populations derived from different zygotes.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The transference of either one or both of the lungs from one human or animal to another.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
Disorders of the blood and blood forming tissues.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
A family composed of spouses and their children.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Transference of an organ between individuals of the same species or between individuals of different species.
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Immunological rejection of leukemia cells following bone marrow transplantation.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
Bone loss due to osteoclastic activity.
An encapsulated lymphatic organ through which venous blood filters.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A general term for various neoplastic diseases of the lymphoid tissue.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
The transference of a pancreas from one human or animal to another.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
Tumors or cancer located in bone tissue or specific BONES.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Multiple subtypes or forms are recognized based on presence or absence of TAU PROTEIN inclusions. FTLD includes three clinical syndromes: FRONTOTEMPORAL DEMENTIA, semantic dementia, and PRIMARY PROGRESSIVE NONFLUENT APHASIA.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
Antibodies produced by a single clone of cells.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.
The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Diseases of BONES.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Summarizing techniques used to describe the pattern of mortality and survival in populations. These methods can be applied to the study not only of death, but also of any defined endpoint such as the onset of disease or the occurrence of disease complications.
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Excessive formation of dense trabecular bone leading to pathological fractures; OSTEITIS; SPLENOMEGALY with infarct; ANEMIA; and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
The number of CELLS of a specific kind, usually measured per unit volume or area of sample.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Irradiation of one half or both halves of the body in the treatment of disseminated cancer or widespread metastases. It is used to treat diffuse metastases in one session as opposed to multiple fields over an extended period. The more frequent treatment modalities are upper hemibody irradiation (UHBI) or lower hemibody irradiation (LHBI). Less common is mid-body irradiation (MBI). In the treatment of both halves of the body sequentially, hemibody irradiation permits radiotherapy of the whole body with larger doses of radiation than could be accomplished with WHOLE-BODY IRRADIATION. It is sometimes called "systemic" hemibody irradiation with reference to its use in widespread cancer or metastases. (P. Rubin et al. Cancer, Vol 55, p2210, 1985)
A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Proteins prepared by recombinant DNA technology.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
The immune responses of a host to a graft. A specific response is GRAFT REJECTION.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man,, August 20, 2004)
Group of disorders which feature accumulations of active HISTIOCYTES and LYMPHOCYTES, but where the histiocytes are not LANGERHANS CELLS. The group includes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; SINUS HISTIOCYTOSIS; xanthogranuloma; reticulohistiocytoma; JUVENILE XANTHOGRANULOMA; xanthoma disseminatum; as well as the lipid storage diseases (SEA-BLUE HISTIOCYTE SYNDROME; and NIEMANN-PICK DISEASES).
The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunized donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Transplantation between animals of different species.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
A type of ALPHAPAPILLOMAVIRUS associated with high risk for anogenital neoplasms.
Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
The grafting of bone from a donor site to a recipient site.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Mice bearing mutant genes which are phenotypically expressed in the animals.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
The process of bone formation. Histogenesis of bone including ossification.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
The number of LYMPHOCYTES per unit volume of BLOOD.
Pathological processes of the OVARIES or the TESTES.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A decrease in the number of NEUTROPHILS found in the blood.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Pathological processes of the LIVER.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.
A subnormal level of BLOOD PLATELETS.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (1/8007)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

Risk factors for severe hemorrhagic cystitis following BMT. (2/8007)

Hemorrhagic cystitis (HC) is a common toxicity of preparative regimens for bone marrow transplantation (BMT). Severe HC often requires prolonged and expensive hospitalization, and occasionally can result in death. To investigate the risk factors for severe HC, we conducted a retrospective study among 1908 patients who received BMTs at the University of Minnesota during 1974 to 1993. A previous report from our institution reported on 977 of these patients. We identified all patients with genitourinary complication within 100 days post-BMT from the BMT database. Medical charts for these patients were reviewed to determine whether the patient had HC and also the grade of HC. A total of 208 HC cases were identified during the study period. Of them, 92 patients had severe HC, an incidence of 5% (95% CI = 4-6%). We found that grade II-IV graft-versus-host disease (RR = 2.56; 95% CI = 1.43-4.56), use of busulfan (RR = 2.69; 95% CI = 1.35-5.35), and age at transplant (RR = 2.20; 95% CI = 1.27-3.81, for age of 10-30 compared to age of 0-9) were related to an increased risk of HC. In contrast, transplant year was inversely associated with the risk of HC (trend test, P < 0.01). We did not find any significant difference in HC with the use of prophylactic Mesna.  (+info)

Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (3/8007)

Current guidelines for the treatment of catheter-related bacteraemia (CRB) advise against central venous catheter (CVC) exchange because of the potential risk of prolonging infection. However, there are no consistent data proving this recommendation. We evaluated prospectively the usefulness of CVC exchange by guidewire for the treatment of CRB in patients undergoing BMT or intensive chemotherapy. CVC exchange was considered when fever and positive blood cultures persisted after 2 days of adequate antimicrobial therapy and no potential source of bacteraemia other than CVC could be identified. The guidewire exchange was preceded and followed by a slow infusion of adequate antimicrobial therapy. Bacteraemia was confirmed as catheter-related by demonstrating concordance between isolates from the tip and blood cultures by pulsed-field electrophoresis of genomic DNA. This procedure was performed in 19 episodes of bacteraemia during a 1-year period. Fourteen episodes (74%) were catheter-related and 71% of these were due to coagulase-negative staphylococci. Guidewire replacement was accomplished uneventfully 4 days after development of sepsis (range 3-6). In all cases, clinical signs of sepsis disappeared in less than 24 h after replacement. Definitive catheter withdrawal was carried out a median of 16 days (range 3-42) after guidewire exchange; in all cases, the tip culture was negative. We conclude that CVC replacement by guidewire under adequate antimicrobial therapy may be a reasonable option for the treatment of CRB when antimicrobial therapy alone has been unsuccessful.  (+info)

The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. (4/8007)

At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchoscopy for CMV receive pre-emptive ganciclovir. In order to determine the utility of other screening methods for CMV, we prospectively performed weekly CMV antigenemia, and blood, urine and throat cultures from time of engraftment to day 120 post-BMT in 126 consecutive patients. Pre-emptive ganciclovir was given to 11/81 patients (13.6%) because of a positive surveillance bronchoscopy for CMV. Results of CMV blood, urine and throat cultures and the antigenemia assay done prior to or at the time of the surveillance bronchoscopy were analyzed for their ability to predict the bronchoscopy result. The antigenemia test had the highest positive and negative predictive values (72% and 96%, respectively). The ability of these tests to predict CMV disease was evaluated in the 70 patients with a negative surveillance bronchoscopy who did not receive pre-emptive ganciclovir. Of 19 cases of active CMV disease, CMV antigenemia was positive in 15 patients (79%) a mean of 34 days preceding symptoms. Blood cultures were positive in 14/19 patients (74%) a mean of 31 days before onset of disease. CMV antigenemia is useful for predicting the surveillance bronchoscopy result, and also predicts the development of CMV disease in the majority of patients missed by the surveillance bronchoscopy.  (+info)

Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation. (5/8007)

Lupus anticoagulant antibodies have never been reported to disappear after either allogeneic or autologous bone marrow transplantation in humans. We report the first case of disappearance of lupus anticoagulant antibodies in a patient without systemic lupus erythematosus or clinical evidence of other autoimmune disorders, who received an allogeneic bone marrow transplant as treatment for chronic myeloid leukemia. Although marrow transplantation is not a recognized therapy for antiphospholipid syndrome, our observation should be considered another example of the capability of intensive chemo-radiotherapy followed by stem cell transplantation to ablate a pathologic marrow clone resulting in an autoimmune disorder and improve, or even cure, some severe autoimmune diseases.  (+info)

Rapid autologous marrow recovery and eradication of infectious mononucleosis despite severe immunosuppression following second transplantation for aplastic anemia. (6/8007)

A patient with aplastic anemia failed to respond to immunosuppressive therapy and first marrow transplantation (BMT). Recovery of autologous hematopoiesis was rapid following a second stem cell transplant with a non-myeloablative preparatory regimen. The autologous immune response to infectious mononucleosis (IM) 4 weeks post-transplant was normal despite recent and ongoing severe immunosuppression.  (+info)

Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal. (7/8007)

GVHD is one of the most frequent complications of BMT and recently nephrotic syndrome (NS) has been described as a manifestation of chronic GVHD. Here, we present an AA patient who developed NS 1 year after BMT when cyclosporine was stopped. Renal biopsy showed focal sclerosis associated with membranous deposits. He also had other clinical manifestations of chronic GVHD: sicca-like syndrome and colestasis. After 15 days of CsA therapy, he experienced a remarkable improvement in the NS and GVHD as a whole. We comment on immunological mechanisms that could be involved in the pathogenesis of this manifestation.  (+info)

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. (8/8007)

Conjugation of gonadotropin-releasing hormone (GnRH) analogues GnRH-III, MI-1544, and MI-1892 through lysyl side chains and a tetrapeptide spacer, Gly-Phe-Leu-Gly (X) to a copolymer, poly(N-vinylpyrrolidone-co-maleic acid) (P) caused increased antiproliferative activity toward MCF-7 and MDA-MB-231 breast, PC3 and LNCaP prostate, and Ishikawa endometrial cancer cell lines in culture and against tumor development by xenografts of the breast cancer cells in immunodeficient mice. MCF-7 cells treated with P-X-1544 and P-X-1892 displayed characteristic signs of apoptosis, including vacuoles in the cytoplasm, rounding up, apoptotic bodies, bleb formation, and DNA fragmentation. Conjugates, but not free peptides, inhibited cdc25 phosphatase and caused accumulation of Ishikawa and PC3 cells in the G2/M phase of the cell cycle after 24 h at lower doses and in the G1 and G2 phases after 48 h. Since P-X-peptides appear to be internalized, the increased cytotoxicity of the conjugates is attributed to protection of peptides from proteolysis, enhanced interaction of the peptides with the GnRH receptors, and/or internalization of P-X-peptide receptor complexes so that P can exert toxic effects inside, possibly by inhibiting enzymes involved in the cell cycle. The additional specificity of P-X-peptides compared with free peptides for direct antiproliferative effects on the cancer cells but not for interactions in the pituitary indicates the therapeutic potential of the conjugates.  (+info)

TY - JOUR. T1 - Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome. AU - Kato, T.. AU - Tsuge, I.. AU - Inaba, J.. AU - Kato, K.. AU - Matsuyama, T.. AU - Kojima, S.. PY - 1999. Y1 - 1999. N2 - We report a case of an 11-year-old boy who underwent successful bone marrow transplantation for X-linked hyper-IgM syndrome (XHIM). The donor was an HLA-matched brother. The patient was conditioned with busulfan, cyclophosphamide and anti-thymocyte globulin. He received 4.7 x 108 marrow cells per kg from the donor. Prophylaxis against graft-versus-host disease consisted of cyclosporine and short-term methotrexate. The clinical course after the bone marrow transplantation was uneventful, and 12 months after transplantation the patient was doing well with no need for therapy. We examined expression of the CD40 ligand (CD40L) on the patients activated T lymphocytes and in vitro production of immunoglobulins by his lymphocytes. Although expression of CD40L was totally absent ...
TY - JOUR. T1 - Recovery of erythropoiesis following allogeneic bone marrow transplantation for chronic lymphocytic leukaemia-associated pure red cell aplasia. AU - De Vetten, M. P.. AU - Van Gelder, M.. AU - De Greef, G. E.. PY - 2001. Y1 - 2001. N2 - Pure red cell aplasia is a rare condition, that can be either idiopathic or associated with a lymphoproliferative disorder. The latter is considered to result from T cell-mediated suppression of haematopoiesis, and usually responds well to treatment with immunosuppressive medication. We describe a patient with B-CLL-associated pure red cell aplasia who did not respond to several courses of immunosuppressive treatment. Erythropoiesis was finally restored after allogeneic bone marrow transplantation.. AB - Pure red cell aplasia is a rare condition, that can be either idiopathic or associated with a lymphoproliferative disorder. The latter is considered to result from T cell-mediated suppression of haematopoiesis, and usually responds well to ...
TY - JOUR. T1 - Epstein-barr-virus-related malignant b cell lymphoplasmacytic lymphoma following allogeneic bone marrow transplantation for aplastic anemia. AU - Forman, Stephen J.. AU - Sullivan, John L.. AU - Wright, Christine. AU - Ratech, Howard. AU - Racklin, Barbara. AU - Blume, Karl G.. PY - 1987. Y1 - 1987. N2 - The development of B cell lymphoma has been reported to occur in recipients of a variety of organ transplants, including some patients who have received an allogeneic bone marrow graft. In this report, we describe a patient with severe aplastic anemia who developed a malignant B cell lymphoplasmacytoid proliferation 48 days after undergoing allogeneic marrow transplantation from her HLA-matched MLC-nonreactive brother. Immunologic studies showed this malignancy to be a mixed polyclonal and monoclonal proliferation in donor ceils. Virologie studies documented Epstein Bare infection of the cells. A review of the literature suggests that graft-versus-host disease and treatment of ...
View the Pediatric Bone Marrow Transplantation Program statistics for St. Louis Childrens Hospital including number of procedures, statistics for both autologous and allogeneic patients and survivor ratings. For more information on the Pediatric Bone Marrow Transplant Program, call 314-454-KIDS (5437).
TY - JOUR. T1 - Lymphoproliferative disorders following allogeneic bone marrow transplantation. T2 - The Vancouver experience. AU - Micallef, I. N.M.. AU - Chhanabhai, M.. AU - Gascoyne, R. D.. AU - Shepherd, J. D.. AU - Fung, H. C.. AU - Nantel, S. H.. AU - Toze, C. L.. AU - Klingemann, H. G.. AU - Sutherland, H. J.. AU - Hogge, D. E.. AU - Nevill, T. J.. AU - Le, A.. AU - Barnett, M. J.. N1 - Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 1998. Y1 - 1998. N2 - Between June 1988 and May 1996, 428 patients underwent allogeneic BMT (288 related donor (RD) and 140 unrelated donor (UD)) at the Vancouver General Hospital. Eight patients (UD six and RD two) developed a post-transplant lymphoproliferative disorder (PTLD). Median age at BMT was 38 years (range 22-51). Five of the six UD allografts were T cell depleted. Cyclosporine ± methotrexate was used for GVHD prophylaxis, All eight patients developed GVHD; in six this was refractory to treatment with corticosteroids. Rabbit ...
TY - JOUR. T1 - Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. AU - Oh, H.. AU - Gale, R. P.. AU - Zhang, M. J.. AU - Passweg, J. R.. AU - Ino, T.. AU - Murakami, H.. AU - Ohno, R.. AU - Rowlings, P. A.. AU - Sobocinski, K. A.. AU - Tanimoto, M.. AU - Tomonaga, M.. AU - Weisdorf, D. J.. AU - Horowitz, M. M.. PY - 1998. Y1 - 1998. N2 - There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemia-free survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant ...
An advanced pediatric bone marrow transplant is available through the International Medicine Department at Sheba Medical Center in Israel. Learn more now.
Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Hauke, R.J.; Greiner, T.C.; Smir, B.N.; Vose, J.M.; Tarantolo, S.R.; Bashir, R.M.; Bierman, P.J. // Bone Marrow Transplantation;6/15/98, Vol. 21 Issue 12, p1271 Epstein-Barr virus-associated lymphoproliferative disorders have been frequently reported as a complication of solid organ and allogeneic bone marrow transplantation. Their occurrence is rare after autologous bone marrow transplantation (BMT) with only five published reports in the literature.... ...
TY - JOUR. T1 - Bone marrow engraftment and GVHD following bone marrow transplantation across a concordant xenogeneic barrier (mouse to rat). AU - Li, H.. AU - Selvaggi, G.. AU - Ricordi, C.. AU - Inverardi, L.. PY - 1997/7/7. Y1 - 1997/7/7. UR - UR - U2 - 10.1016/S0041-1345(97)00288-1. DO - 10.1016/S0041-1345(97)00288-1. M3 - Article. C2 - 9193584. AN - SCOPUS:0030979295. VL - 29. SP - 2190. EP - 2191. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 4. ER - ...
TY - JOUR. T1 - Prospective study of endocrine side-effects following bone marrow transplantation in childhood. AU - Bozzola, M.. AU - Locatelli, F.. AU - Cisternino, M.. AU - Bonetti, F.. AU - Gambarana, D.. AU - Giorgiani Zecca, G. M.. AU - De Stefano, P.. AU - Lorini, R.. AU - Severi, F.. PY - 1991. Y1 - 1991. N2 - An increasing number of children with various hematologic malignancies become long-term survivors following treatment with high dose chemotherapy, total body irradiation (TBI) and bone marrow transplantation (BMT). The doses of chemotherapy and irradiation used in transplant preparative regimens may affect endocrine function. Radiation may directly impair hypothalamic, pituitary, thyroid and gonadal function in a dose-dependent manner. Prospective study is needed to evaluate the long-term endocrine side effects of BMT.. AB - An increasing number of children with various hematologic malignancies become long-term survivors following treatment with high dose chemotherapy, total body ...
Goals: A retrospective study of pretransplantation risk factors predisposing to liver injury following bone marrow transplantation (BMT). Background: Liver complications are a major cause of morbidity and mortality following BMT. Determination of the pretransplantation factors that are likely to lead to liver injury may allow earlier diagnosis after BMT and may possibly improve prognosis. Study: Medical records of BMT patients were reviewed, and results of serial liver function tests and HBV/HCV serology during the pre- and posttransplantation 1-year period were noted. Presence of liver injury was defined as alanine aminotransferase levels twice the upper limit of normal. Forty-four allogeneic and 17 autologous BMTs, performed between 1990 and 2000, were analyzed in the study. Results and Conclusion: One-year survival was 77% (34 of 44 patients) for allogeneic BMT and 52% (9 of 17 patients) for autologous BMT. Seventy-two percent (32 of 44) of allogeneic transplant recipients and 47% (8 of 17) ...
TY - JOUR. T1 - Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation. AU - Champlin, R.. AU - Gajewski, J.. AU - Feig, S.. AU - Giorgi, J.. AU - Lyddane, N.. AU - Lee, K.. AU - Schmidt, I.. AU - Winston, D.. AU - Ho, W.. AU - Reichert, T.. N1 - Copyright: Copyright 2004 Elsevier B.V., All rights reserved.. PY - 1989. Y1 - 1989. UR - UR - M3 - Article. C2 - 2495694. AN - SCOPUS:0024602334. VL - 21. SP - 2947. EP - 2948. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 1 III. ER - ...
Polymerase chain reaction (PCR) is a very potent method enabling the amplification of target DNA sequences at least 10(5)-10(6) fold. The efficacy of PCR is measured by its specificity, efficiency (yield quantity) and fidelity. On the basis of PCR specificity, it is possible to differentiate host genom from virus or bacterial genom if they are in the host bloodstream. It is possible to make a precise diagnosis of an infectious disease. The result of bone marrow transplantation can also be more quickly predicted than by other techniques. Prognosis of engraftment following an allogeneic bone marrow transplantation was obtained by PCR amplification of the hypervariable region (HVR) lying on the 3end of the apolipoprotein B gene. This HVR polymorphism of the largest human gene (apoB) is very informative, considering that 16 alleles are registered in the Belgrade population. It is necessary to detect the HVR genotype of donor and host before and after allogenic bone marrow transplantation. ...The aim ...
TY - JOUR. T1 - Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors. AU - Shuhart, M. C.. AU - Myerson, D.. AU - Spurgeon, C. L.. AU - Bevan, C. A.. AU - Sayers, M. H.. AU - McDonald, G. B.. PY - 1996/4/1. Y1 - 1996/4/1. N2 - In March 1992, 12 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center received blood components from donors who were anti-HCV-nonreactive by first generation ELISA but whose serum later tested anti-HCV-reactive to a second generation ELISA. All these blood components were further tested for anti-HCV using a second-generation RIBA and for HCV RNA by polymerase chain reaction. Recipient sera were tested for HCV RNA prior to and following blood component infusion. Blood components from four donors were positive for HCV RNA. All recipients of HCV RNA-positive blood components became viremic on the first day tested post-infusion. In addition, two recipients of HCV RNA-negative blood ...
TY - JOUR. T1 - Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. AU - Frassoni, Francesco. AU - Labopin, Myriam. AU - Powles, Ray. AU - Mary, Jean Yves. AU - Arcese, William. AU - Bacigalupo, Andrea. AU - Bunjes, Donald. AU - Gluckman, Eliane. AU - Ruutu, Tapani. AU - Schaefer, Ulrich W.. AU - Sierra, Jorge. AU - Vernant, Jean Paul. AU - Willemze, Roel. AU - De Witte, Theo. AU - Gorin, Norbert Claude. PY - 2000/4/22. Y1 - 2000/4/22. N2 - Background: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors ...
Gonadal function after allogenic bone marrow transplantation for thalassaemia. Social integration of the older thalassaemic patient
We discuss clinical strategies for the prophylaxis and treatment of both acute and chronic graft-versus-host disease (GVHD) with particular attention to children. Grades II to IV acute GVHD occur in 10 to 50% of patients given an allogeneic transplantation of haemopoietic stem cells (HSCT) from a genotypically HLA-identical donor. A significantly higher incidence and severity of the disease is reported in patients receiving transplants from partially matched family donors or unrelated volunteers. Younger individuals or patients receiving HSCT from younger donors develop GVHD less frequently than do older recipients. Severe acute GVHD is characterised by a significant decrease in survival probability, even though the graft-versus-leukaemia activity associated with both acute and chronic GVHD may reduce the risk of leukaemia relapse. Prophylaxis of acute GVHD usually consists of in vivo post-grafting immunosuppression with cyclosporin alone or in combination with methotrexate; methotrexate alone ...
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When certain stem cells from a donor are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells. Removing the T cells from the donor cells before transplant may stop this from happening.. PURPOSE: This randomized phase III trial is studying donor bone marrow that is treated in the laboratory using two different devices to compare how well they work in treating patients who are undergoing a donor bone marrow transplant for hematologic cancer. ...
Intensive, myelosuppressive therapy is necessary to maximize outcomes for patients with acute myeloid leukemia (AML). A comparison was made of 3 aggressive postremission approaches for children and adolescents with AML in a randomized trial, CCG-2891. A total of 652 children and adolescents with AML who achieved remission on 2 induction regimens using identical drugs and doses (standard and intensive timing) were eligible for allocation to allogeneic bone marrow transplantation (BMT) based on matched related donor status (n = 181) or randomization to autologous BMT (n = 177) or to aggressive high-dose cytarabine-based chemotherapy (n = 179). Only 115 patients (18%) refused to participate in the postremission phase of this study. Overall compliance with the 3 allocated regimens was 90%. At 8 years actuarial, 54% +/- 4% (95% confidence interval) of all remission patients remain alive. Survival by assigned regimen (intent to treat) is as follows: allogeneic BMT, 60% +/- 9%; autologous BMT, 48% ...
TY - JOUR. T1 - Autologous bone marrow transplantation for patients with advanced chronic myelogenous leukemia. AU - Nagamura-Inoue, Tokiko. AU - Tojo, Arinobu. AU - Ikebuchi, Kenji. AU - Takahashi, Satoshi. AU - Ogura, Hiromi. AU - Shindoh, Eiichi. AU - Nagamura, Fumitaka. AU - Uemura, Naoki. AU - Watari, Kiyoshi. AU - Irie, Seiji. AU - Setoyama, Misao. AU - Tajika, Kenji. AU - Nakayama, Michihiro. AU - Nagayama, Hitomi. AU - Kobayashi, Yukio. AU - Shirafuji, Naoki. AU - Sato, Noriharu. AU - Okamoto, Shin ichiro. AU - Ozawa, Keiya. AU - Tani, Kenzaburo. AU - Asano, Shigetaka. PY - 1997/12. Y1 - 1997/12. N2 - We report on seven chronic myelogenous leukemia (CML) patients who received autologous bone marrow transplantation (ABMT) using bone marrow (BM) cells while at the chronic phase (CP) under the various treatments. Of the seven patients, four progressed to accelerated phase (AP) in 83-248 weeks after onset and three patients entered blastic crisis (BC) in 84-171 weeks after onset. All ...
different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. Addition of a seconds profile, publications, research topics, and co-authors
We offer bone marrow, peripheral blood stem cell, and cord blood transplants for a wide range of diseases, including cancer, blood disorders, immune system diseases, genetic diseases, and bone marrow failure syndromes.Our highly trained medical team understands the application of research-based therapies, and cares for the unique needs of children undergoing bone marrow transplantation. In addition to physicians and nurse practitioners, our team includes a transplant coordinator, social worker, care coordinator, nutritionist, pharmacist, child life specialist, radiation oncologists, psychiatrist, and physical therapist.
BackgroundPneumonia carries significant morbidity and mortality in leukemic and bone marrow transplant patient. The development of pulmonary infiltrates in the setting of such immunocompromise raises concern for both infectious and non-infectious etiologies, some of which are potentially treatabl. Performing bronchoscopy provides several different options for sampling the lower respiratory tract. Among these, bronchoalveolar lavage (BAL) is especially effective at collecting samples from the alveoli and has been shown to be associated with less risk than transbonchial biops. We sought to examine the effect of antimicrobial treatment on BAL results in a large study population of leukemic and bone marrow transplant patients.Subjects and MethodsThis retrospective chart review was performed at a single academic cancer center. A power analysis was performed to determine the appropriate sample size. The patients were selected from those who had undergone an inpatient bronchoscopy in reverse chronological
TY - JOUR. T1 - A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. AU - Adkins, Douglas R.. AU - Irvin, Rebecca. AU - Kuhn, John. AU - Boldt, David H.. AU - Roodman, G. David. AU - Salzman, Donna. AU - Freytes, Cesar. AU - Von Hoff, D. D.. AU - LeMaistre, C. F.. PY - 1993/6. Y1 - 1993/6. N2 - Dacarbazine (DTIC) is a chemotherapy drug which has antitumor activity at standard doses, exhibits a steep dose-response effect in vitro, and is associated with relatively few non-hematologic toxicities. These characteristics suggest a potential role for this drug in bone marrow transplant preparative regimens. To pursue this hypothesis, 16 patients with refractory solid tumors were enrolled in a phase I study of single agent DTIC to determine the dose of DTIC requiring bone marrow reinfusion and to define the dose-limiting toxicity and maximum tolerated dose when given with autologous bone marrow rescue. Pharmacokinetics ...
Invasive mold infections (IMIs) are an important cause of morbidity and mortality in patients who are undergoing bone marrow transplantation (BMT). To examine the epidemiology, risk factors, and outcome of IMIs in allogeneic BMT recipients, all cases of mold infection among 94 adult patients who underwent allogeneic BMT at this institution from 1 January 1997 through 31 December 1998 were reviewed retrospectively. Fifteen cases of IMI were identified; infection occurred a median of 102 days after BMT. Aspergillus species was the most common cause of disease, and species other than Aspergillus fumigatus were present in 53% of patients. By multivariate analysis, the variable associated with infection risk was systemic glucocorticosteroid use. Prophylactic antifungal therapy that was targeted to high-risk patients had little effect on disease incidence. These observations suggest that early identification of high-risk patients and better approaches to prevention should be explored, to reduce ...
Competitive bone marrow transplantation assay measures multi-lineage reconstitution of hematopoiesis in irradiated transplant recipient mice. Thus this assay is routinely used to determine haematopoietic stem and progenitor cells (HSPCs) functionality in vivo. The principle of the method is to transplant bone marrow donor cells (derived from transgenic mice of choice) on C57BL6 background together with normal competitor bone marrow. In order to distinguish donor from competitor cells upon transplantation, usually competitor mice are congenic and carry the differential B cell antigen originally designated Ly5.1 and CD45.1.A typical competitive bone marrow transplantation experiment will contain two transplantation groups, donor (transgenic mice of choice and their controls) are transplanted in competition with normal competitors and engraftment efficiency is evaluated in both blood and bone marrow.
TY - JOUR. T1 - Blood and bone marrow transplantation for acute myeloid leukemia. AU - Villela, Luis M.. AU - Bolanos Meade, F Javier. PY - 2009. Y1 - 2009. N2 - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission or those with poor-risk cytogenetics will benefit the most from this approach. With current transplantation techniques, outcomes have improved over recent years. Although relapse and graft-versus-host disease still are important problems faced by these patients, novel approaches have been developed to decrease the risk of complications, with excellent results.. AB - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission ...
A healthy immune system produces T cells that can recognize and react against foreign molecules (antigens) to protect against infection, while leaving normal host cells with self antigens undamaged. All T cells are produced in the thymus from blood stem cells that originate in the bone marrow and migrate through the blood circulation to the thymus. During aging, the thymus shrinks in size (involutes) and T cell production is limited, causing a poorly functioning immune system. T cell production and immune recovery is also slow and incomplete after bone marrow transplantation in older patients. In previous studies we showed that the thymus grows rapidly and T production is very robust in new-born mice. We also showed that during the new-born period, a growth factor called Vascular Endothelial Growth Factor (VEGF) is made at high levels in the thymus. When VEGF is inhibited in new-borns, T cell production falls, suggesting that this molecule plays an important role in thymic growth during this ...
And after more than 50 years of tireless investigations, this procedure has become standard treatment of hematologic malignancies. Despite major advances, bone marrow transplantation is still a difficult and evolving field. A newly published clinical resource called Clinical Manual of Blood and Bone Marrow Transplantation is a valuable addition to the literature on transplantation. Well-Organized Format EDITED BY Drs. Syed A. Abutalib and Parameswaran Hari, the book provides a concise practical expert review in a well-organized format of 42 chapters, each annotated with numerous practical headings to enhance focused learning. Stem cell transplantation is highly specialized, and this book is targeted for teachers and clinicians in the field. Each of the 42 chapters focuses on a particular topic and provides numerous reference tables and figures. The structure provides a neat and handy compendium for daily work caring for bone marrow transplant patients. It also offers a complete set of ...
OBJECTIVES: I. Compare the disease free survival of patients with leukemia, myelodysplasia, or lymphoblastic lymphoma after treatment with conventional (non-T cell depleted) or T cell depleted unrelated donor bone marrow transplantation. II. Compare the incidence of primary and secondary graft failure, acute and chronic graft-vs-host disease, complications (infection, veno-occlusive disease, interstitial pneumonitis), and relapse in these patients after these treatments. III. Compare the incidence of other malignancies, lymphoproliferative disorders, and post-transplant myelodysplasia in these patients after these treatments.. OUTLINE: This is a randomized, multicenter study. Patients will be stratified according to institution. Patients are assigned to one of two treatment arms, one with conventional bone marrow transplantation (arm I) and one with T cell depletion of the bone marrow (arm II). Arm I: Patients receive cyclophosphamide on days -6 and -5. Total body irradiation (TBI) is ...
TY - JOUR. T1 - Leukocyte low density lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo. T2 - Bone marrow transplantation studies in the mouse. AU - Fazio, Sergio. AU - Hasty, Alyssa H.. AU - Carter, Kathy J.. AU - Murray, Alisa B.. AU - Price, James O.. AU - Linton, MacRae R.F.. PY - 1997/2/1. Y1 - 1997/2/1. N2 - The targeted disruption of the low density lipoprotein (LDL) receptor gene in mice results in accumulation of plasma LDL cholesterol and in predisposition to diet-induced aortic atherosclerosis. Although the liver is the central organ for receptor mediated clearance of LDL, the in vivo role of other organs and tissues in LDL catabolism has not been directly studied. Since bone marrow-derived cells such as blood leukocytes and tissue macrophages express LDL receptors and contribute a large cell mass to the body, we designed bone marrow transplantation (BMT) experiments to reconstitute LDL receptor null mice [LDL-R(-/-)] with marrow obtained from LDL-R wild-type ...
The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis ...
How to cite websites, books, podcasts, articles, journals, movies, and more in Bone Marrow Transplantation style. Bone Marrow Transplantation Example. A referencing guide from Citationsy, the worlds best reference management tool.
Intravenous literature: Wiersma, P., Schillie, S., Keyserling, H., Watson, J.R., De, A., Banerjee, S.N., Drenzek, C.L., Arnold, K.E., Shivers, C., Kendrick, L., Ryan, L.G., Jensen, B., Noble-Wang, J. and Srinivasan, A. (2010) Catheter-Related Polymicrobial Bloodstream Infections among Pediatric Bone Marrow Transplant Outpatients, Atlanta, Georgia, 2007. Infection Control & Hospital Epidemiology. 31, [ePub ahead of print]. Abstract:. Objective: To identify risk factors for polymicrobial bloodstream infections (BSIs) in pediatric bone marrow transplant (BMT) outpatients attending a newly constructed clinic affiliated with a children’s hospital.. Methods: All 30 outpatients treated at a new BMT clinic during September 10â€21, 2007, were enrolled in a cohort study. The investigation included interviews, medical records review, observations, and bacterial culture and molecular typing of patient and environmental isolates. Data were analyzed using exact conditional logistic ...
Established in 1911, The University of Tennessee Health Science Center aims to improve human health through education, research, clinical care and public service. The UT Health Science Center campuses include colleges of Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing and Pharmacy. Patient care, professional education and research are carried out at hospitals and other clinical sites across Tennessee. Endowed professorships, Research Centers of Excellence, and continuing relationships with research and healthcare facilities across Tennessee ensure that both basic science and applied research stay focused on contemporary health topics.
Pediatr Dent. 1989 Mar;11(1):37-42. Clinical Trial; Controlled Clinical Trial; Research Support, Non-U.S. Govt; Research Support, U.S. Govt, P.H.S.
GHN Healthcare Services is a leading Medical treatment Assistance Company based in New Delhi (National Capital region), India. The Organization actively engaged in providing Medical assistance to foreign Patients who choose to travel to India for quality medical care at a reasonable cost. GHN Healthcare Services is associated with 25+ Top-Notch Hospitals and has a network of 500+ Super Specialists to offer world-class medical care at a reasonable cost.
We analyzed the clinical course and risk factors of 18 patients with poor engraftment after allogeneic bone marrow transplantation (BMT), defined as absolute neutrophil count below 0.1×10 9/1 28 days post-BMT. Significant risks associated with non-engraftment included HLA one antigen mismatch, BMT from matched unrelated donor, and a low dose of colony-forming units-granulocyte-macrophage (,10 4/kg). Examined by a semi-quantitative analysis of polymorphic microsatellite markers, donor DNA chimerism on day 28 was found to be predictive of treatment outcome. Seven patients had detectable donor DNA, varying from 43 to 100%. Five of them responded to granulocyte colony-stimulating factor (G-CSF) and achieved engraftment. Two were given further infusions of peripheral blood hematopoietic stem cells (PBSC) from the same donors, resulting in engraftment in one of them. Eleven patients had no detectable donor DNA, and none responded to G-CSF. Autologous regeneration occurred in six of these patients, ...
Our first blog post highlights the life-saving bone marrow transplant procedure.. The Important Work of a Bone Marrow Transplant. For patients with certain conditions such sickle cell disease, lymphoma, aplastic anemia, and neuroblastoma, myelodysplastic syndrome (MDS), and including possible fatal blood cancers, like lymphoma and leukemia, a bone marrow transplant offers a chance for a cure and a longer life. Its also sometimes necessary to repair damaged marrow (where blood cells are manufactured) as a result of chemotherapy for cancer, as was the case with Good Morning Americas host Robin Roberts. We are happy to hear that Robin is expected back to Good Morning Amerca on February 20th after taking time off for her bone marrow transplant.. Bone Marrow Transplant Donor Awareness. The largest U.S. registry for bone marrow donors Be The Match National Marrow Donor Program encourages people to get involved or volunteer. Be The Match helps to connect donor matches with patients in need of a ...
Fludarabine is a nucleoside analog with potent antitumor and immunosuppressive properties used in conditioning regimens of pediatric allogeneic hematopoietic cell transplantation (alloHCT) to promote stem cell engraftment.. This is a single-center, pharmacokinetic-pharmacodynamic (PK-PD) study investigating the clinical pharmacology of fludarabine in 45 children undergoing alloHCT at UCSF Benioff Childrens Hospital.. Patients would receive fludarabine regardless of whether or not they decide to consent to PK sampling.. Fludarabine doses will not be adjusted based on PK data.. We will apply the combination of a D-optimality-based limited sampling strategy and population PK methodologies to determine specific factors influencing fludarabine exposure in pediatric alloHCT recipients and identify exposure-response relationships.. Subjects will undergo PK sampling of plasma (f-ara-a) and intracellular (f-ara-ATP) drug concentrations over the duration of fludarabine therapy (3 to 5 days).. To evaluate ...
Question - Successful bone marrow transplant for AML. Now have back pain, cough, loss of appetite. Why?. Ask a Doctor about Bone marrow transplant, Ask an Oncologist
Allogeneic bone marrow transplantation (stem cell transplant) in aplastic anemia (costs for program #80341) ✔ Andreasklinik Cham Zug ✔ Department of Oncology and Hematology ✔
Allogeneic bone marrow transplantation (stem cell transplant) in acute lymphoblastic leukemia (ALL) (costs for program #260823) ✔ University Hospital Münster ✔ Department of Hematology, Hemostaseology, Oncology and Pneumology (Medical Department A) ✔
article: Cell therapy of hip osteonecrosis with autologous bone marrow grafting - Minerva Ortopedica e Traumatologica 2008 December;59(6):365-72 - Minerva Medica - Journals
To determine whether graft-versus-leukemia (GVL) reactions are important in preventing leukemia recurrence after bone marrow transplantation, we studied 2,254 persons receiving HLA-identical sibling bone marrow transplants for acute myelogenous leukemia (AML) in first remission, acute lymphoblastic …
TY - JOUR. T1 - Percutaneous endoscopic gastrostomy tubes in pediatric bone marrow transplant patients. AU - Kaur, Sunpreet. AU - Ceballos, Clare. AU - Bao, Ruijun. AU - Pittman, Nanci. AU - Benkov, Keith. PY - 2013/3/1. Y1 - 2013/3/1. N2 - BACKGROUND AND OBJECTIVES:: Nourishing a child undergoing bone marrow transplant (BMT) is essential, but the optimal method to achieve this is not established. The objectives of the study were to investigate the incidence and risk factors for complications of gastrostomy tubes in patients with BMT. METHODS:: A retrospective chart review was conducted of pediatric patients who received a percutaneous endoscopic gastrostomy (PEG) either for BMT or for other indications during a 3-year period. Occurrences of complications, absolute neutrophil count (ANC) at time of PEG placement, and ANC at time of complication were reviewed for both BMT and the comparison group. RESULTS:: Of the 11 subjects in the BMT group, 4 (36%) had a major complication of infection related ...
Looking for online definition of autologous bone marrow transplantation in the Medical Dictionary? autologous bone marrow transplantation explanation free. What is autologous bone marrow transplantation? Meaning of autologous bone marrow transplantation medical term. What does autologous bone marrow transplantation mean?
Despite a growing understanding of the link between intestinal inflammation and resident gut microbes, longitudinal studies of human flora before initial onset of intestinal inflammation have not been reported. Here, we demonstrate in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intestinal inflammation secondary to graft-versus-host disease (GVHD) is associated with major shifts in the composition of the intestinal microbiota. The microbiota, in turn, can modulate the severity of intestinal inflammation. In mouse models of GVHD, we observed loss of overall diversity and expansion of Lactobacillales and loss of Clostridiales. Eliminating Lactobacillales from the flora of mice before BMT aggravated GVHD, whereas reintroducing the predominant species of Lactobacillus mediated significant protection against GVHD. We then characterized gut flora of patients during onset of intestinal inflammation caused by GVHD and found patterns mirroring those in mice. We also ...
TY - JOUR. T1 - Caregiver responses and needs. T2 - An ambulatory bone marrow transplant model. AU - Grimm, Patricia M.. AU - Zawacki, Kristin L.. AU - Mock, Victoria. AU - Krumm, Sharon. AU - Frink, Barbara B.. N1 - Copyright: Copyright 2013 Elsevier B.V., All rights reserved.. PY - 2000. Y1 - 2000. N2 - PURPOSE: This longitudinal, descriptive outcomes study was conducted to compare the emotional responses and needs of the caregivers of patients who undergo bone marrow transplantation (BMT) for hematologic malignancies, as observed in an inpatient/outpatient (IPOP) setting with those in an inpatient setting. DESCRIPTION OF STUDY: A convenience sample of 43 caregivers for patients undergoing either autologous or allogeneic BMT was selected from both the inpatient unit (n = 26) and the IPOP ambulatory setting (n = 17). Emotional responses were measured by the Profile of Mood States. The importance and satisfaction of informational, patient-care, and psychological needs were assessed with the ...
Allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen (HLA)-identical donor is currently the only proven curative treatment for chronic granulomatous disease. Hematopoietic stem cell transplantation with alternative donors is associated with higher morbidity and mortality. Therefore, we performed in vitro fertilization and preimplantation HLA matching combined with female sexing for hematopoietic stem cell transplantation in chronic granulomatous disease. Ethical and psychological issues were considered carefully. We used in vitro fertilization with X-enriched spermatozoa followed by preimplantation genetic diagnosis to identify female HLA-genoidentical embryos in a family in need of a suitable donor for their boy affected with severe X-linked chronic granulomatous disease. Two preimplantation genetic diagnosis cycles were performed in the family. In the second cycle, 2 HLA-genoidentical female embryos were transferred and a singleton pregnancy was obtained, ...
TY - JOUR. T1 - Autologous blood stem cell versus bone marrow transplantation. AU - Korbling, M.. AU - Juttner, C.. AU - Henon, P.. AU - Kessinger, A.. PY - 1992. Y1 - 1992. UR - UR - M3 - Article. C2 - 1355683. AN - SCOPUS:0026752883. VL - 10. SP - 144. EP - 148. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. IS - SUPPL. 1. ER - ...
TY - JOUR. T1 - Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. AU - Katsanis, E.. AU - Anderson, P. M.. AU - Filipovich, A. H.. AU - Hasz, D. E.. AU - Rich, M. L.. AU - Loeffler, C. M.. AU - Ochoa, A. C.. AU - Weisdorf, D. J.. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 1991. Y1 - 1991. N2 - We evaluated the proliferation, cytolytic function, and phenotypic characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral blood mononuclear cells (PBMCs) from 44 patients with leukemia or non-Hodgkins lymphoma (NHL) treated with multiagent chemotherapy or following bone marrow transplantation (BMT). BMT patients had decreased cell growth with only a 1.35 ± 0.25 (autologous BMT for acute lymphoblastic leukemia [ALL]), 1.24 ± 0.25 (autologous BMT for NHL), and 0.8 ± 0.1 (allogeneic BMT for leukemia) mean fold increase by day 5 of culture compared with ...
Pediatric anaplastic large cell lymphoma (ALCL) is a chemosensitive malignancy, but about 30% of patients experience relapse. In most of these patients, a second complete remission is obtainable with salvage chemotherapy, though relapse free survival rates are as low as 30-60%. Herein, we report a 6-year-old boy with relapsed anaplastic lymphoma kinase (ALK) positive ALCL successfully treated with vinblastine monotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reduced intensity conditioning (RIC) regimen, from his father. One HLA locus from the father was mismatched. The boy had neither severe graft-versus-host disease nor transplantation related complications. He is currently well and has remained disease free for 10 months, to date, since transplantation. Allo-HSCT with a RIC regimen may be a promising treatment strategy for relapsed ALK positive ALCL based on obtaining graft-versus lymphoma effects as well as reducing transplantation-related mortality.
A 16 year old man underwent an allogeneic bone marrow transplantation (BMT) from an HLA identical sibling donor for acute lymphoblastic leukaemia in 1984. He developed chronic graft versus host disease involving the skin and kidneys. At day 400 after BMT his condition was complicated by obstructive airways disease, which was partially responsive to azathioprine and steroids. Five years after withdrawal of immunosuppressive treatment he developed dyspnoea and decreased pulmonary function test results, and steroid treatment was resumed. Fibrobronchoscopy revealed the presence of a mucoepidermoid carcinoma in the left main bronchus. After surgical laser resection, there was gradual clinical and functional improvement. There was no evidence of recurrence one year after surgery.. ...
Looking for online definition of bone marrow transplant in the Medical Dictionary? bone marrow transplant explanation free. What is bone marrow transplant? Meaning of bone marrow transplant medical term. What does bone marrow transplant mean?
TY - JOUR. T1 - Allogeneic bone marrow transplantation for chronic granulomatous disease. AU - Rappeport, Joel M.. AU - Newburger, Peter E.. AU - Goldblum, Randall M.. AU - Goldman, Armond S.. AU - Nathan, David G.. AU - Parkman, Robertson. PY - 1982/12. Y1 - 1982/12. UR - UR - U2 - 10.1016/S0022-3476(82)80017-6. DO - 10.1016/S0022-3476(82)80017-6. M3 - Article. C2 - 6754900. AN - SCOPUS:0020385877. VL - 101. SP - 952. EP - 955. JO - Journal of Pediatrics. JF - Journal of Pediatrics. SN - 0022-3476. IS - 6. ER - ...
AIMS--To study the association between cytomegalovirus (CMV) excretion and interstitial pneumonitis in allogeneic bone marrow transplant (BMT) recipients, with reference to donor and recipient CMV antibody response. METHODS--The incidence of CMV excretion was prospectively studied in 62 allogeneic bone marrow transplantations performed on adults and children. All recipients received CMV seronegative blood products. Prophylaxis with high dose acyclovir and CMV immune globulin was given to high risk patients (donor or recipient, or both, CMV seropositive). RESULTS--CMV excretion was detected in eight of 26 (31%) high risk patients but in only one of 36 low risk patients (donor and recipient both CMV seronegative). Five of the eight (63%) excretors in the high risk category developed CMV, of whom four (80%) belonged to the seropositive recipient/seronegative donor group, and included the three CMV seropositive recipients whose CMV complement fixation antibody titres were 64 or greater before ...
Background: Given the presumed key role for autoreactive lymphocytes in multiple sclerosis (MS), treatment strategies have been developed to ablate lymphocyte activity. Intrathecal lymphocyte activation can be measured by CSF-soluble(s)CD27.. Objective: To determine the effect of maximum whole-body immune ablation on two different markers that detect lymphocyte activation in CSF-oligoclonal IgG bands and levels of CSF-sCD27.. Design, setting and patients: The study quantified sCD27 levels and assessed the presence of oligoclonal IgG bands in CSF samples of secondary progressive patients with MS treated by autologous bone-marrow transplantation. In eight individuals, CSF was taken before and 6-9 months after conditioning. CSF-sCD27 levels were compared with other MS and non-inflammatory neurological disease controls. Regarding the effect of stem-cell transplantation on CSF oligoclonal bands, the study analysed pooled data of this and four other international studies on stem-cell transplantation ...
Infections are responsible for a large part of the morbidity and mortality after BMT because of the sustained impairment of host defenses. We report a case of cutaneous infection caused by Mycobacterium szulgai in a boy who underwent BMT with marrow from a matched unrelated donor.. ...
Fingerprint Dive into the research topics of Detection of HHV-6B in post-mortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis.. Together they form a unique fingerprint. ...
View details of top bone marrow transplantation hospitals in Ambience Island, Gurgaon. Get guidance from medical experts to select best bone marrow transplantation hospital in Ambience Island
Dr. Dharma Choudhary, Best Doctor in India, Best Bone Marrow Transplant specialist in B L Kapur Hospital, New Delhi, Bone marrow Transplant in Specialist in India, Doctor for Bone Marrow Transplant in India, Health in India, Hematologist at B L Kapur Hospital, new Delhi, Hematologist in Delhi. Bone Marrow Transplant in Delhi, Hospital for bone marrow transplant in India
Different Asthma Phenotypes in Adult Asthma: Comparison of Allergic Asthma and Nonallergic Asthma Chih-Hao Chang, Horng-Chyuan Lin, Meng-Heng Hsieh, Guan-Yuan Chen, Fu-Tsai Chung, Chih-Teng Yu, Han-Pin Kuo Anti-inflammatory Activity and Mucolytic Effect of Ambroxol in Patients with Stable Chronic Bronchitis ─ A Preliminary Report Chien-Ming Chu, Chung-Chieh Yu, Huang-Ping Wu, Bor-Yiing Jiang, Jo-Chi Tseng, Chung-Ching Hua, Teng-Jen Yu, Yu-Chih Liu, Wen-Pin Shieh Spontaneous Remission in Goodpasture Syndrome and Relapse 5 Years Later - A Case Report Fang-Chuan Dai, Mei-Chin Wen, Jeng-Yuan Hsu, Gwan-Han Shen IgG4-Related Sclerosing Disease of the Lung ─ Case Report Chih-Heng Kuo, Wen-Hu Hsu, Yi-Chen Yeh Wegeners Granulomatosis with Tracheal Involvement and Severe Pulmonary Hemorrhage Hui-Wen Shih, Hou-Tai Chang, Cheng-Yu Chang, Shin-Lung Cheng Late Onset Non-Infectious Interstitial Lung Disease Following Bone Marrow Transplantation: A Case Report Mei-Ling Chen, Yung-Hsiang Hsu, En-Ting Chang
TY - JOUR. T1 - Therapeutic angiogenesis by bone marrow mononuclear cell transplantation. T2 - limitation in the elderly and augmentation by angiopoietin 1 gene therapy. AU - Kondo, Takahisa. AU - Kobayashi, Koichi. AU - Inoue, Natsuo. AU - Izawa, Hideo. AU - Shintani, Satoshi. AU - Okumura, Kenji. AU - Murohara, Toyoaki. AU - Numaguchi, Yasushi. N1 - Copyright: MEDLINE® is the source for the citation and abstract of this record.. PY - 2007/1. Y1 - 2007/1. UR - UR - U2 - 10.3143/geriatrics.44.65. DO - 10.3143/geriatrics.44.65. M3 - Review article. C2 - 17337854. AN - SCOPUS:34047248695. VL - 44. SP - 65. EP - 68. JO - Japanese Journal of Geriatrics. JF - Japanese Journal of Geriatrics. SN - 0300-9173. IS - 1. ER - ...
In an effort to find new strategies to personalize treatment for pediatric patients, Seattle Childrens has opened the first clinical trial applying next-generation T-cell receptor (TCR) sequencing and single-cell gene expression analysis to better understand how the immune system drives both inflammatory bowel disease (IBD) in pediatric autoimmunity patients and graft-versus host disease (GVHD) in pediatric bone marrow transplant (BMT) patients.. The PREDICT (Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation) trial is expected to first provide clinicians new information about why IBD arises in children, allowing them to tailor treatment plans to each patient. The trial will later expand to include BMT patients with the goal of identifying the immunologic changes that occur when a patient develops GVHD, the deadliest complication associated with BMT. BMT is used to treat a range of pediatric conditions from leukemia to inherited bone marrow failure ...
TY - JOUR. T1 - Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function. T2 - The LateTIME randomized trial. AU - Traverse, Jay H.. AU - Henry, Timothy D.. AU - Ellis, Stephen G.. AU - Pepine, Carl J.. AU - Willerson, James T.. AU - Zhao, David X.M.. AU - Forder, John R.. AU - Byrne, Barry J.. AU - Hatzopoulos, Antonis K.. AU - Penn, Marc S.. AU - Perin, Emerson C.. AU - Baran, Kenneth W.. AU - Chambers, Jeffrey. AU - Lambert, Charles. AU - Raveendran, Ganesh. AU - Simon, Daniel I.. AU - Vaughan, Douglas E.. AU - Simpson, Lara M.. AU - Gee, Adrian P.. AU - Taylor, Doris A.. AU - Cogle, Christopher R.. AU - Thomas, James D.. AU - Silva, Guilherme V.. AU - Jorgenson, Beth C.. AU - Olson, Rachel E.. AU - Bowman, Sherry. AU - Francescon, Judy. AU - Geither, Carrie. AU - Handberg, Eileen. AU - Smith, Deirdre X.. AU - Baraniuk, Sarah. AU - Piller, Linda B.. AU - Loghin, Catalin. AU - Aguilar, ...
Hill, GR, Ferrara, JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. vol. 95. 2000. pp. 2754-9. (Highlights the importance of the gastrointestinal tract in the pathogenesis of GVHD). Przepiorka, D, Weisdorf, D, Martin, P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. vol. 15. 1995. pp. 825-8. (Key article on grading of acute GVHD). Cahn, JY, Klein, JP, Lee, SJ. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. vol. 106. 2005. pp. 1495-1500. (Key article on grading of acute GVHD). Eapen, M, Horowitz, MM, Klein, JP. Higher mortality after allogeneic peripheral-blood transplantation compared with bone ...
TY - JOUR. T1 - Donor bone marrow infusions are tolerogenic in human renal transplantation. AU - Ciancio, G.. AU - Garcia-Morales, R.. AU - Mathew, J.. AU - Carreno, M.. AU - Burke, G. W.. AU - Ricordi, C.. AU - Kenyon, N.. AU - Esquenazi, V.. AU - Cirocco, R.. AU - Tzakis, A.. AU - Miller, J.. PY - 2001/1/1. Y1 - 2001/1/1. UR - UR - U2 - 10.1016/S0041-1345(00)02485-4. DO - 10.1016/S0041-1345(00)02485-4. M3 - Article. C2 - 11267299. AN - SCOPUS:0035087150. VL - 33. SP - 1295. EP - 1296. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 1-2. ER - ...
bone marrow donor programme - List of free articles written by article author bone marrow donor programme which can be reprinted or published on your blog, website or ezine.
Approaches for haploidentical bone marrow transplantation (BMT) without T-cell depletion have been designed using new transplant strategies, including anti-thymocyte globulin (ATG) preparative regimens, granulocyte colony-stimulating factor-primed grafts, post-transplantation rapamycin, or high-dose cyclophosphamide (Cy) in combination with other immunosuppressive agents for graft-versus-host disease (GVHD) prophylaxis. These strategies ensured fast hematologic engraftment across the human leukocyte antigen (HLA) barrier with an acceptable incidence of GVHD. Long-term follow-up results from different transplant centers suggest that unmanipulated transplantation may provide an alternative strategy in the haploidentical setting without requiring the technical expertise and cost of ex vivo T-cell depletion. This review discusses immune reconstitution and factors associated with clinical outcomes following unmanipulated haploidentical hematopoietic stem cell transplantation (HSCT), and compares ...
Leading Bone Marrow Transplant Specialist and doctor in India talks about bone marrow transplant or BMT, Stem Cell Transplant treatment for thalassemia, leukemia, sickle-cell disease and few other diseases in India for international patients looking for BMT or bone marrow transplant or stem cell transplant hospitals and doctors in India. Bone Marrow Transplant Package cost in India. The rest is here ...
CORTICOSTEROIDS. Corticosteroids have been the mainstay treatment for NMO in both acute and maintenance phase. Methylprednisolone has been used since 1970 as a potent anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic and autoimmune origin. In addition, it is also widely used in prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation and acute spinal cord injury. Corticosteroids exert a wide array of physiologic effects including modulation of carbohydrate, protein and lipid metabolism, and maintenance of fluid and electrolyte homeostasis. Moreover, cardiovascular, immunologic, musculoskeletal, endocrine and neurologic physiologic functions are influenced by corticosteroids. Therefore, not only the positive effects can be observed, but also many adverse events can be originated from corticosteroids use. These adverse events can be seen acutely like ...
TY - JOUR. T1 - Cellular immune responses of human cadaver donor bone marrow cells and their susceptibility to commonly used immunosuppressive drugs in transplantation. AU - Mathew, James M.. AU - Carreno, Manuel. AU - Zucker, Keith. AU - Fuller, Laphalle. AU - Kenyon, Norma. AU - Esquenazi, Violet. AU - Ricordi, Camillo. AU - Tzakis, Andreas G.. AU - Miller, Joshua. N1 - Copyright: Copyright 2007 Elsevier B.V., All rights reserved.. PY - 1998/4/15. Y1 - 1998/4/15. N2 - Background. The cascade of immunological effects brought about by donor bone marrow cell (DBMC) infusions in human organ transplantation, especially in the context of continuous pharmacologic immunosuppression, is not fully understood. Yet, in inbred rodents and even primates, administration of specific bone marrow cells has caused a state of acquired immunologic tolerance. Methods. In vitro mixed lymphocyte culture (MLC) and cell-mediated lympholysis (CML) culture systems were used to compare the responding and regulatory ...
TY - JOUR. T1 - Therapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb. AU - de Nigris, Filomena. AU - Williams-Ignarro, Sharon. AU - Sica, Vincenzo. AU - DArmiento, Francesco P.. AU - Lerman, Lilach O.. AU - Byrns, Russell E.. AU - Sica, Giacomo. AU - Fiorito, Carmela. AU - Ignarro, Louis J.. AU - Napoli, Claudio. PY - 2007/4/25. Y1 - 2007/4/25. N2 - Lower-limb ischemia is a major health problem especially when associated to hypercholesterolemia. Because of the absence of effective treatment in the advanced stages of the disease, amputation is undertaken to alleviate unbearable symptoms. Since tissue ischemia and hypercholesterolemia are associated with an overwhelming generation of oxygen radicals, metabolic intervention with antioxidants and l-arginine can induce beneficial effects beyond those achieved by a novel therapeutic approach represented by the use of autologous ...
Some people experience bone marrow problems and their bone marrow is destroyed. It is the semi-solid tissue that is found in the spongy areas of bones. Some diseases of the bone marrow are not curable such as multiple myeloma. So, this part should be replaced. The bone marrow transplant procedure is performed to the patients who experience severe problems such as cancer. So, they take cells that are normally found in bone marrow and these cells are filtered. If these cells become germ-free after filtering, then they are placed in the same location of the patient. Otherwise, the cells of other persons are transplanted in the region. Bone marrow transplant The bone marrow produces three types of cells namely the red blood, white blood and platelets. This operation involves complications also and sometimes, it is life-threatening. Some of the complications that arise are graft host disease and graft failure. The blood forming cells of the patient are extracted and replaced with the germ-free ...
TY - JOUR. T1 - Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. AU - Siefer, Anne K.. AU - Longo, Dan L.. AU - Harrison, Christie Lee. AU - Reynolds, Craig W.. AU - Murphy, William J. PY - 1993/10/15. Y1 - 1993/10/15. N2 - Purified populations of natural killer (NK) cells were obtained from mice with severe combined immune deficiency (SCID). SCID spleen cells were cultured and activated with recombinant human interleukin-2 (rhIL-2) in vitro. The activated NK cells were then transferred with syngeneic BALB/c bone marrow cells (BMC) and rhIL-2 into lethally irradiated syngeneic recipients to determine their effect on long-term hematopoietic reconstitution. On analysis, the transfer of rhIL-2-activated NK cells along with BMC resulted in significant increases in splenic and BM hematopoietic progenitor cells when compared with those for mice not receiving NK cells. Histologic and flow ...
The Transplant Committee of the Cancer and Leukemia Group B (CALGB) was organized in the mid-1980s at a time when high-dose chemotherapy with autologous bone marrow transplant was being actively investigated as treatment for a number of solid tumors and hematologic malignancies. Preliminary data from single institution studies had generated considerable interest in the use of high-dose chemotherapy and autologous bone marrow transplant for both metastatic and early-stage high-risk breast cancer, so that such treatment was widely employed at many centers despite the lack of definitive evidence from controlled trials that it was efficacious. Therefore, CALGB designed protocol 9082 to definitively test whether high-dose chemotherapy and autologous bone marrow transplant was superior to intermediate dose chemotherapy in women with stage II breast cancer and ≥10 positive axillary lymph nodes (1).. At the time this trial was initiated, the role of autologous transplantation as treatment for ...
TY - JOUR. T1 - Pharmacodynamic studies of cyclosporine in marrow transplant recipients. T2 - A comparison of three assay methods. AU - McGuire, Timothy R. AU - Yee, Gary C. AU - Emerson, S.. AU - Gmur, D. J.. AU - Carlin, J.. PY - 1992/1/1. Y1 - 1992/1/1. N2 - We investigated the correlation between trough cyclo-sporine concentration in plasma measured by polyclonal fluorescence polarization immunoassay (FPIA) and polyclonal radioimmunoassay (RIA) or in whole blood measured by high-performance liquid chromatography (HPLC) and the risk of renal dysfunction or acute graft-versus-host disease in 29 patients undergoing allogeneic bone marrow transplantation for leukemia. The FPIA and RIA values were highly correlated (r=0.93) and on the average CsA concentrations measured by FPIA were 1.56 times higher than those measured by RIA. Ten patients developed renal dysfunction and 10 developed grades II-IV acute GVHD. Although univariate analysis showed that plasma CsA concentrations measured by either ...
SEATTLE - Study demonstrates that marrow transplantation using HLA-matched unrelated donors can be safe and effective therapy for patients with chronic myeloid leukemia (CML) in chronic phase. Seattle researchers also believe that transplantation should not be limited to younger people, under the age of 40 years. Fred Hutchinson Cancer Research Center researchers published the results of their study in the April 2, 1998, issue of The New England Journal of Medicine.. Transplantation has been shown to be the cure for many blood disorders and inherited diseases, including CML. One obstacle has always been the identification of a suitably matched donor. Previously, it was believed that only those CML patients with an HLA-matched sibling donor had an option for curative treatment. This study concludes that marrow transplantation from an HLA-matched unrelated donor can be the treatment of choice for many CML patients and should be considered early in the course of disease to optimize ...
Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy.. Stem cell transplant is used to produce blood in the body and also some other components for persons immune system to work. Persons stem cells are recovered and harvested in a system. These cells were then put back into the body intravenously.. For more information about bone marrow stem cell transplant and stem cell therapies, contact us. Its free!. Simply click the button below. ...
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia This study is currently recruiting participants. Verified April 2012 by…
Results:. Three and one half years after single-dose TBI, 51 of the 74 patients (69%) were alive and cataracts had developed in all of these 51 patients. Cataracts developed in 18 of the 90 (20%) patients treated with fractionated TBI, with an 83% (95% CI, 63% to 100%) risk for lens opacification at 6 years\f. Cataracts developed in only 1 of the 33 (3%) patients treated with chemotherapy alone. Incidence of cataracts is higher and lens opacification occurs earlier after single-dose TBI than after fractionated TBI (P , 0.01). With Cox regression analysis, the use of irradiation (relative risk, 21.0), the mode of irradiation (relative risk, 7.4), and the use of steroid treatment (relative risk, 2.9) for more than 3 months after bone marrow transplantation increased the risk for cataract formation. In contrast, age, sex, and chronic graft-versus-host disease did not influence the rate of cataract development. The probability of requiring cataract surgery after 6 years was 85% (CI, 75% to 95%) for ...
definition of ABMR, what does ABMR mean?, meaning of ABMR, Autologous Bone Marrow Reinfusion, ABMR stands for Autologous Bone Marrow Reinfusion
Clinical usefulness of bone marrow transplantation (BMT) remains limited by myocardial damage during the post-transplantation period. Measurements of plasma atrial and brain natriuretic peptides (ANP, BNP) during the acute post-transplantation period could serve to monitor cardiac complications since these peptides are known to increase in heart failure depending on its severity. We prospectively analyzed ANP and BNP levels from 14 days before to 100 days after BMT in 46 consecutive patients undergoing allogeneic (n=42) and autologous (n=4) transplantation. Cardiac performance was assessed by echocardiography and radionuclide ventriculography. BNP and ANP levels of the patients on admission (baseline: day-14) were 16.3±13.3 pg/ml and 14.4±8.8 pg/ml, respectively. There were two different types of changes in the BNP and ANP levels. The 21 patients in group I showed dual peaks of elevation on day 1 (BNP=164.4±136.0 pg/ml, ...
Bone marrow transplantation. *Gene therapy. Career paths and training[edit]. The examples and perspective in this article deal ...
bone marrow transplantation. *angiogenesis for cardiovascular diseases. See also[edit]. *Angiogenesis. *Bone growth factor ... For the circulatory system and bone marrow in which cells can occur in a liquid suspension and not bound up in solid tissue, it ...
"Bone Marrow Transplantation. 41 (2): 159-65. doi:10.1038/sj.bmt.1705929. PMC 2892221. PMID 18037943.. ... or bone marrow (less than 10 percent of nucleated bone marrow cells are tumors). ... Stage 4: Dissemination of tumor to distant lymph nodes, bone marrow, bone, liver, or other organs except as defined by Stage 4S ... Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid". New England Journal of Medicine. 341 (16): 1165-73. doi: ...
"Bone Marrow Transplantation. 31 (12): 1704105. doi:10.1038/sj.bmt.1704105.. *^ Fine, Jo-David; Manes, Becky; Frangoul, Haydar ( ... at least four patients have died in the course of either preparation for or institution of bone marrow transplantation for ... the severe immunosuppression that bone marrow transplantation requires causes a significant risk of serious infections in ... As of 2008 clinical research at the University of Minnesota has included a bone marrow transplant to a 2-year-old child who is ...
June 2008). "Stem cell transplantation for primary immunodeficiencies". Bone Marrow Transplant. 41 Suppl 2: S83-6. doi:10.1038/ ... Bone marrow transplant may be possible for Severe Combined Immune Deficiency and other severe immunodeficiences. Virus-specific ... T-Lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that has proven to ...
It can also involve bone marrow transplantation. Information on prognosis is limited by the rarity of the condition. Prognosis ... Acute erythroid leukemias can be classified as follows: 50% or more of all nucleated bone marrow cells are erythroblasts, ... Orazi, Attilio; O'Malley, Dennis P.; Arber, Daniel A. (2006-07-20). Illustrated Pathology of the Bone Marrow. Cambridge ... These cells may constitute 90% or more of the marrow elements. Despite this lack of myeloblasts, these cases should be ...
Association of Community Cancer Centers, National Bone Marrow Transplantation Research Network, National Gene Vector Laboratory ... In 2017, City of Hope was planning a Bone Marrow Transplant Reunion Day and Survivors Day.[10] The hospital also participates ... "City of Hope Reaches Historic Treatment Milestone with 10,000th Bone Marrow Transplant". BusinessWire. 2011-01-13. Archived ... which includes transplants of bone marrow, peripheral blood stem cells collected by apheresis, and umbilical cord stem cells.[9 ...
"False Hope : Bone Marrow Transplantation for Breast Cancer". Oxford University Press. Retrieved 7 May 2014. Eddy DM (1992). " ... "High-Dose Chemotherapy with Autologous Bone Marrow Transplantation for the Treatment of Metastatic Breast Cancer". 10. Journal ... under Eddy's guidance were tested and vindicated during the national controversy over high dose chemotherapy and bone marrow ...
"Gianotti-Crosti syndrome associated with cytomegalovirus antigenemia after bone marrow transplantation". Bone Marrow ... Transplantation. 20 (8): 691-3. doi:10.1038/sj.bmt.1700945. PMID 9383234. Chandrasekaran M, Mukherjee S (September 2007). " ...
HLA non-identical bone marrow transplants in a series of 10 patients". Bone Marrow Transplantation. 29 (9): 759-762. doi: ... Aggressive treatment with antibiotics is required and bone marrow transplant is common. Patients undergoing bone marrow ... Transplantation is a simple process. Bone marrow product is infused through a central vein over a period of several hours. The ... Transplantation of stem cells are taken from the bone marrow, peripheral blood or umbilical cord of healthy, matched donors. ...
... was found to correlate with the absence of GvHD after bone marrow transplantation, while decreased numbers of Tr1 markedly ... Bone Marrow Transplantation. 37 (2): 207-212. doi:10.1038/sj.bmt.1705218. ISSN 0268-3369. PMID 16284610.. ... Transplantation research has shown, that donor Tr1 in response to recipient alloantigens, ... "Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms". Immunological Reviews. ...
"Unexpected complications after bone marrow transplantation in transfusion-dependent children". Bone Marrow Transplantation. 12 ... Bone marrow transplantation (BMT) can cure hematological aspects of DBA. This option may be considered when patients become ... Typically, a diagnosis of DBA is made through a blood count and a bone marrow biopsy. A diagnosis of DBA is made on the basis ... This is in contrast to Shwachman-Bodian-Diamond syndrome, in which the bone marrow defect results primarily in neutropenia, and ...
"G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept". Bone Marrow Transplantation. 50 ( ... and transplantation". Biology of Blood and Marrow Transplantation. 12 (6): 672-82. doi:10.1016/j.bbmt.2006.02.006. PMID ... White blood cells The G-CSF-receptor is present on precursor cells in the bone marrow, and, in response to stimulation by G-CSF ... hematopoietic system G-CSF is also a potent inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into the ...
March 1997). "Factors predicting morbidity following hematopoietic stem cell transplantation". Bone Marrow Transplantation. 19 ... Bone Marrow Transplantation. 37 (5): 499-502. doi:10.1038/sj.bmt.1705262. PMID 16415895. Suzuki A, Nakauchi H, Taniguchi H ( ... Perry SS, Wang H, Pierce LJ, Yang AM, Tsai S, Spangrude GJ (April 2004). "L-selectin defines a bone marrow analog to the thymic ... 1984). "Bone marrow monosomy 7: hematologic and clinical manifestations in childhood and adolescence". Hematological Oncology. ...
"HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide". Bone Marrow ... "Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide". Seminars in ... Bone Marrow Transplantation. 24 (12): 1367-8. doi:10.1038/sj.bmt.1702097. PMID 10627651. Vigouroux D, Voltaire L (1995). "[ ... Lohrmann HP (1984). "The problem of permanent bone marrow damage after cytotoxic drug treatment". Oncology. 41 (3): 180-4. doi: ...
January 25, 2007). False Hope: Bone Marrow Transplantation for Breast Cancer. Oxford University Press. pp. 222-223. ISBN ... Bone Marrow Transplantation. 25 (7): 797-799. doi:10.1038/sj.bmt.1702222. PMID 10745268. Goldberg, Stuart; Pecora, Andrew; et ... to become assistant director of stem cell and bone marrow transplantation from 1990 to 1993. He went on to become the program's ... cells as it relates to chemotherapy treatment and bone marrow transplantation for the treatment of non-Hodgkin's lymphoma (NHL ...
Bone Marrow Transplantation. 47 (10): 1377-1378. doi:10.1038/bmt.2012.33. PMC 4547590. PMID 22388279. Poll-The, Bwee; Engelen, ... The accepted treatment for affected boys presenting with the cerebral childhood form of the disease is a bone marrow transplant ... which is then transplanted into the patients using a similar procedure as for a bone marrow or stem cell transplant. Gene ... Cartier, Nathalie; Aubourg, Patrick (27 October 2009). "Hematopoietic Stem Cell Transplantation and Hematopoietic Stem Cell ...
Bone Marrow Transplantation. 52 (7): 941-949. doi:10.1038/bmt.2016.340. PMID 28112752. Ewend MG, Brem S, Gilbert M, Goodkin R, ... a type of bone marrow transplant, in order to reduce the white blood cell count in the recipient. Use under this protocol, ... It is also used as part of a chemotherapeutic protocol in preparation for hematological stem cell transplantation, ...
Bone Marrow Transplantation. 35 (6): 595-599. doi:10.1038/sj.bmt.1704797. PMID 15665849. "Medical Abstract". namazi hospital ... leukocytes and antigenemia for diagnosis of active human cytomegalovirus infection in bone marrow transplant patients". ... The first living-related kidney transplantation performed at Shiraz University Hospital dates back to 1968. The hospital has an ...
... and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease". Bone Marrow Transplantation. 43 (1): ... also known as bone marrow transplant, to try to prevent the disease from getting worse. Data are sparse but there is a known ... Some children with LAL-D have had an experimental therapy called hematopoietic stem cell transplantation (HSCT), ... liver transplantation was necessary in most patients. Infants with LAL deficiencies typically show signs of disease in the ...
... bone marrow transplantation; and immunotherapy. In all, the center has 25 separate programs for treating different cancers. ... These include: Blood & Marrow Transplantation Program Breast Cancer Program Endocrine Tumors Program Esophageal Cancer Program ...
Bone Marrow Transplantation. 47 (1): 46-53. doi:10.1038/bmt.2011.15. PMID 21358688. Zohren F, Czibere A, Bruns I, et al. ( ... Bone Marrow Transplantation. 44 (12): 785-92. doi:10.1038/bmt.2009.83. PMID 19430496. Schmid C, Weisser M, Ledderose G, Stötzer ... Biology of Blood and Marrow Transplantation. 18 (3): 466-72. doi:10.1016/j.bbmt.2011.09.006. PMID 21963618. Chemnitz JM, von ... March 2012). "Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or ...
Bone Marrow Transplantation. 20 (9): 789-791. doi:10.1038/sj.bmt.1700969. PMID 9384484. Duggan, J.M.; Wolf, M.D.; Kauffiman, C. ... While the spread of chromoblastomycosis to the muscle and bone is usually rare, in cases where antifungal drugs alone are ...
"E Donnall Thomas (1920-2012)". Bone Marrow Transplantation. 48 (1): 1. 2013. doi:10.1038/bmt.2012.254. ISSN 1476-5365. S2CID ...
Bone Marrow Transplantation. 28 (12): 1171-3. doi:10.1038/sj.bmt.1703288. ISSN 0268-3369. PMID 11803363. Livermore DM ( ... infection of the bone and bone marrow); and uncomplicated skin and soft tissue infections caused by S. pyogenes or S. aureus. ... Bone marrow suppression was not identified during Phase III trials, in which treatment did not exceed 21 days. Although some ... Bone marrow suppression, characterized particularly by thrombocytopenia (low platelet count), may occur during linezolid ...
Bone Marrow Transplantation. 31 (8): 705-712. doi:10.1038/sj.bmt.1703870. PMID 12692611. Haas M et al. 50th ASTRO congress 2008 ... randomized clinical trial in patients undergoing bone marrow transplantation. This trial demonstrated that Caphosol, used in ... were evaluated in 95 patients undergoing bone marrow transplantation. The treatment arm received 4 topical fluoride treatments ... The results showed: More than twice as many bone marrow transplant patients avoided oral mucositis by using Caphosol Duration ...
Bone Marrow Transplantation. 15 (6): 825-828. ISSN 0268-3369. PMID 7581076. Jennette, J. C.; Falk, R. J.; Bacon, P. A.; Basu, N ...
Bone Marrow Transplantation. 31 (5): 361-9. doi:10.1038/sj.bmt.1703816. PMID 12634727. FLT3 signaling v t e. ...
Bone Marrow Transplantation. 38 (5): 365-370. doi:10.1038/sj.bmt.1705450. ISSN 1476-5365. PMID 16862164. S2CID 31056997. " ... methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation ... Bhorade, S. M.; Stern, E. (2009-01-15). "Immunosuppression for Lung Transplantation". Proceedings of the American Thoracic ... Abdi, Reza; Spencer Martin; Steven Gabardi (2009). "Immunosuppressive Strategies in Human Renal Transplantation - Induction ...
International Bone Marrow Transplant Registry". Bone Marrow Transplantation. 24 (3): 283-7. doi:10.1038/sj.bmt.1701899. PMID ... After bone marrow transplantation, T cells present in the graft, either as contaminants or intentionally introduced into the ... A great deal of current research on allogeneic bone marrow transplantation involves attempts to separate the undesirable graft- ... Results of matched sibling transplants for malignant diseases". Bone Marrow Transplantation. 13 (5): 597-611. PMID 8054913. ...
... bone marrow transplantation, and HIV-1 infection. Annual Review of Immunology. 2000, 18: 529-560. ISSN 0732-0582. PMID 10837068 ... American Journal of Transplantation. September 2015, 15 (9): 2431-42. PMID 25943855. doi:10.1111/ajt.13288.. ... The role of peripheral T-cell deletion in transplantation tolerance. Philosophical Transactions of the Royal Society of London ... IL-10 Induces T Cell Exhaustion During Transplantation of Virus Infected Hearts. Cellular Physiology and Biochemistry. 2016, 38 ...
1996) 4. Established the Laminar Air Flow Room and the Bone Marrow Transplantation Center. (1995) The hospital is accessible ...
"Bone Marrow Transplant" redirects here. For the journal abbreviated Bone Marrow Transplant, see Bone Marrow Transplantation ( ... Bone marrow transplantation usually requires that the recipient's own bone marrow be destroyed (myeloablation). Prior to the ... Thomas' work showed that bone marrow cells infused intravenously could repopulate the bone marrow and produce new blood cells. ... Wikimedia Commons has media related to Hematopoietic stem cell transplantation.. *Bone marrow transplant - How it is performed ...
"Bone Marrow Res 2012: 787414. PMC 3398573. PMID 22830032. *↑ William JB; Prabakaran, Rajamanickam; Ayyappan, Subbu (2011). " ... Gahrton G, Björkstrand B (2000). "Progress in haematopoietic stem cell transplantation for multiple myeloma". J Intern Med 248 ... 2006). "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". Stem ... "P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow". Clin Chem ...
He was a board member of the Armenian American Chamber of Commerce, International Bone Marrow Donor Registry, President of the ... "Cause of atrioventricular block in patients after heart transplantation". Transplantation journal. "USC AGSA Dinner Dance and ... He co-authored a research article in the peer-reviewed journal Transplantation on "Cause of Atrioventricular Block in Patients ... After Heart Transplantation.". Margarian continued his education at the USC Marshall School of Business and received his MBA in ...
Jude is the first known hospital in the world to cure sickle cell disease through bone marrow transplantation. Today, bone ... marrow transplantation still offers the only cure for sickle cell disease. Members of Kappa Alpha Psi reach out to churches in ...
Then he sutured them together and attached them to the stump of bone to keep them from retracting.[16] This is the first known ... Gift of Life Marrow Registry. *Human Tissue Authority. *LifeSharers. *National Marrow Donor Program ... 2008). "Hand Transplantation: The Innsbruck Experience". Transplantation of Composite Tissue Allografts. pp. 234-250. doi: ... Hand transplantation is a surgical procedure to transplant a hand from one human to another. The "donor" hand usually comes ...
... is a biological treatment option for articular cartilage damage bone marrow stimulating technique in combination with a ... "Autologous chondrocyte transplantation in the treatment of articular cartilage lesions of the talus". Orthopade (in German). ... using tissue engineering with a scaffold derived from a rat meniscus and mesenchymal stromal cells derived from rat bone marrow ... Osteoarthritis is a common condition of cartilage failure that can lead to limited range of motion, bone damage and invariably ...
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ... 2015. Bone marrow transplantation is, as of 2009, the only established use of stem cells. ... PMID 17076602. Bone marrow transplantation is, as of 2009, the only established use of stem cells. ... Bone Marrow Transplant». *↑ Ed Kane. «Stem-cell therapy shows promise for horse soft-tissue injury ...
For a long time, the most efficient approach had been to use bone marrow graft, or hematopoietic stem cell transplantation. ... Because of all these reasons, bone marrow grafts or hematopoietic stem cell transplantation have seen a decrease in their ... The bones themselves may be affected, resulting in short stature. In addition, pebbly, ivory-colored skin lesions may be found ... long term follow-up on patients undergone to hematopoietic stem cell transplantation, Minerva Pediatr. 2013 Oct;65(5):487-96. ...
Specialist services include: cardiology and cardiac surgery, renal and bone marrow transplantation. For a number of these ... transplantation and vascular surgery, with Critical Care, Theatre and Diagnostic Services. ...
KK Ballen, F Verter and J Kurtzberg Umbilical cord blood donation: public or private? Bone Marrow Transplantation (2015), 1-8 ... Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells ...
"Bone Marrow Transplantation. 31: 411-412. doi:10.1038/sj.bmt.1703857.. Pemeliharaan CS1: Banyak nama: authors list (link) ...
Another product is iron, which is used in the formation of new blood cells in the bone marrow.[5] Medicine treats the spleen ... Liver transplantation. *Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt ... They are made of a bone-like material called dentin, which is covered by the hardest tissue in the body-enamel.[8] Teeth have ... The palate is hard at the front of the mouth since the overlying mucosa is covering a plate of bone; it is softer and more ...
The hospital was established in the year 2000 and operates a bone marrow transplantation unit with a focus on the treatment of ... "Sister's Bone Marrow Cures Thalassemia in 26-year-old at Narayana Health City, Bangalore". "Major S ... The hospital provides hematology and bone marrow transplant services for the Major S Nanjundiah and Shanta Nanjundiah Cancer ...
They did the first UK clinical trials of the rubella vaccine, and the first bone marrow transplant and gene therapy for severe ... The hospital is the largest centre for child heart surgery in the UK and one of the largest centres for heart transplantation ...
Bone marrow and stem cell transplantation are effective for all types of cytopenias. However, when a compatible donor cannot be ... Refractory cytopenia - caused by bone marrow not producing healthy blood cells, and can be a result of cancer. ...
Through this process red blood cells are continuously produced in the red bone marrow of large bones. (In the embryo, the liver ... The blood type needs to be determined to prepare for a blood transfusion or an organ transplantation. ... They are also recycled in the bone marrow.[46]. Senescence. The aging red blood cell undergoes changes in its plasma membrane, ... Approximately 2.4 million new erythrocytes are produced per second in human adults.[3] The cells develop in the bone marrow and ...
In the two lobes, hematopoietic precursors from the bone-marrow, referred to as thymocytes, mature into T cells. Once mature, T ... The newly formed organ resembled a normal thymus histologically and molecularly, and upon transplantation it was able to ... Cells in the thymus can be divided into thymic stromal cells and cells of hematopoietic origin (derived from bone marrow ... Schwarz, B. A.; Bhandoola, A. (2006). "Trafficking from the bone marrow to the thymus: a prerequisite for thymopoiesis". ...
... and instead these people should be trialed on reinduction chemotherapy followed by allogeneic bone marrow transplantation. ... Bone pain, joint pain (caused by the spread of "blast" cells to the surface of the bone or into the joint from the marrow ... A bone marrow biopsy provides conclusive proof of ALL, typically with ,20% of all cells being leukemic lymphoblasts.[27] A ... These lymphoblasts build up in the bone marrow and may spread to other sites in the body, such as lymph nodes, the mediastinum ...
In 2016, it inaugurated a bone marrow transplantation unit. It is the second-largest hospital in East Jerusalem, as well as ...
Cells fractionated by SBA do not produce graft vs host disease and can be used in bone marrow transplantation across ... An important application for SBA is the separation of pluripotent stem cells from human bone marrow. ...
A bone marrow biopsy will reveal collagen fibrosis, replacing the marrow that would normally occupy the space.[citation needed] ... The one known curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks.[15] ... Primary myelofibrosis (PMF) is a rare bone marrow blood cancer.[1] It is classified by the World Health Organization (WHO) as a ... The bone marrow in a typical case is hypercellular and diffusely fibrotic. Both early and late in disease, megakaryocytes are ...
Bone Marrow Transplantation for Breast Cancer: Bone Marrow Transplantation for Breast Cancer. Oxford University Press. p. 183. ...
It also occasionally affects spleen, lymph nodes, lungs, kidneys, adrenal glands, bone marrow, and other parts of ... "Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural ...
... high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation". Blood ... "Biology of Blood and Marrow Transplantation. 15 (12): 1628-33. PMC 2861656 . PMID 19896087. doi:10.1016/j.bbmt.2009.07.004.. ... Krumbhaar EB (1919). "Role of the blood and the bone marrow in certain forms of gas poisoning". JAMA. 72: 39-41. doi:10.1001/ ... In very severe myelosuppression, which occurs in some regimens, almost all the bone marrow stem cells (cells that produce white ...
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ... Bone Marrow Transplant". *↑ Kane, Ed. "Stem-cell therapy shows promise for horse soft-tissue injury ... Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a ... A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other tissues". Leukemia, 21 ( ...
... created a bone marrow registry, the Tzu Chi Bone Marrow Bank, in 1993 after a young follower of Cheng Yen was diagnosed ... Smith, Franklin O.; Reaman, Gregory H.; Racadio, Judy M. (26 November 2013). Hematopoietic Cell Transplantation in Children ... the foundation created a bone marrow registry, an effort that eventually caused Taiwan to alter its bone marrow laws, and ... Tzu Chi had registered more than 307,657 bone marrow donors.[45]. College of MedicineEdit. Tzu Chi established the Tzu Chi ...
Figure 1 , Bone Marrow Transplantation. Figure 1. From: Outcome after reduced-intensity conditioning allogeneic SCT for AML in ...
... peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation. ... Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation FREE. W Hasegawa, G R Pond ... Life-threatening neurological complications after bone marrow transplantation in children FREE. D Uckan, M Cetin, Yigitkanli, ... Bone Marrow Transplant 35: 1-16; advance online publication, October 18, 2004; doi:10.1038/sj.bmt.1704716 ...
Bone marrow transplantation replaces faulty bone marrow with healthy bone marrow from a donor. Learn about the possible risks, ... Bone marrow (stem cell) donation (Medical Encyclopedia) Also in Spanish * Bone marrow transplant (Medical Encyclopedia) Also in ... Find a Donor (National Marrow Donor Program) * Learn About Bone Marrow Transplantation as a Treatment Option (Health Resources ... Bone marrow transplant - children - discharge (Medical Encyclopedia) Also in Spanish * Bone marrow transplant - discharge ( ...
Bone marrow transplantation.. -- Features peer-reviewed articles covering all aspects of clinical and basic hemopoietic stem ... Bone marrow transplantation. Bone Marrow Transplant. Abstract:. Features peer-reviewed articles covering all aspects of ... Bone marrow transplantation.. a schema:MediaObject, schema:Periodical, schema:CreativeWork ;. library:oclcnum "958631636" ;. ... Transplantation. schema:alternateName "Bone Marrow Transplant" ;. schema:datePublished "uuuu/9999" ;. schema:description " ...
... and bone marrow (BM)-derived sorted CD4+ and CD8+ T cells of donor mice to T cell depleted bone marrow injected into lethally ... Regulatory Immunotherapy in Bone Marrow Transplantation. Vanessa Morales-Tirado, Wioleta Luszczek, Marié van der Merwe, and ... Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Childrens Research Hospital, 262 Danny Thomas Place, ... H. E. Kohrt, A. B. Pillai, R. Lowsky, and S. Strober, "NKT cells, Treg, and their interactions in bone marrow transplantation ...
Details how the factors that drove clinical use of high-dose chemotherapy with autologous bone marrow transplantation (HDC/ABMT ... Details how the factors that drove clinical use of high-dose chemotherapy with autologous bone marrow transplantation (HDC/ABMT ...
... explains how transplantation is used in the treatment of leukemia. ... Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center, talks about bone marrow ... First, high doses of radiation and/or chemotherapy are used to destroy abnormal bone marrow. Healthy bone marrow - from a donor ... Chief of the Bone Marrow Transplantation Service, ...
In the future, it can allow to abandon bone marrow transplantation and patients will no longer need to wait for suitable donor ... A special bioactive coating of the material helped to increase the rate of division of bone cells by three times. ... developed material that will allow to restore damaged internal bone structure without bone marrow transplantation. It is based ... In the future, it can allow to abandon bone marrow transplantation and patients will no longer need to wait for suitable donor ...
... fellowship program is a one-year program designed to prepare physicians for academic careers in stem cell transplantation, ... The Bone Marrow Transplantation Program at MSK was founded in 1973 and is one of the largest in the country. The Program ... Adult Bone Marrow Transplantation Service. Memorial Sloan Kettering Cancer Center. 1275 York Avenue, Box 400. New York, NY ... The Adult Hematopoietic Stem Cell Transplantation Fellowship Program at Memorial Sloan Kettering Cancer Center is an ...
A fundamental mission of the Hematological Malignancies and Bone Marrow Transplantation program is to enhance our understanding ... The program in Bone Marrow Transplantation (Drs. David E. Avigan, Jon Arnason, Vassiliki Boussiotis, Robin M. Joyce, James D. ... Bone marrow transplantation is uniquely curative for many patients with hematological malignancies due to the targeting of ... Bone marrow transplantation is potentially effective in eliminating blood cancer stem cells through their replacement by normal ...
Do you know which doctor should you consult if you have Bone Marrow Transplantation. This and other commonly asked questions ... Bone Marrow Transplantation - Animation. Animation and slides providing graphic explanation of Bone Marrow Transplantation (BMT ... 1. Which doctors do bone marrow transplantation?. Bone marrow transplantation is performed by physicians including oncologists ... 5. What is the cost of bone marrow transplantation?. The cost for bone marrow transplant may vary for each patient depending on ...
Background Info? Bone marrow transplantation restores stem cells that were destroyed by high doses of ch... ... Read this full essay on Bone Marrow Transplantation. ... and into the bone marrow to draw the marrow out of the bone. ... Bone Marrow Transplantation Essay. 1229 words - 5 pages Background Info? Bone marrow transplantation restores stem cells that ... After the successful bone marrow transplantation, the MHC molecules on cells derived from the donor bone marrow will match the ...
The Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Childrens is a leader in care for hard-to- ... Bone Marrow Transplantation and Immune Deficiency The Division of Bone Marrow Transplantation and Immune Deficiency at ... Our Bone Marrow Transplantation Program. Learn more about our different clinics, the diseases we treat, research efforts, ... Learn more about the conditions we treat, including malignancies, immune deficiencies, bone marrow failure syndromes, ...
View scientific achievements from the Division of Bone Marrow Transplantation and Immune Deficiency in our 2018 Research Annual ... Bone Marrow Transplantation and Immune Deficiency Featured Research. Critical Link Discovered for Dangerous Complication of ... poorly recognized complication that can occur in about 30 percent of people receiving hematopoietic stem cell transplantation ( ...
... transplantation is for patients with relapsed or high risk cancers of the blood, eg leukaemia, lymphoma, myeloma. ... Bone marrow transplantation (or stem cell transplantation) is a well-established procedure for patients with relapsed or high- ... Bone marrow transplantation may also be an option for the treatment of certain non-haematological disorders. ... Home Our services Haematology Specialities list Bone marrow (stem cell) transplantation services ...
This glossary can help you to easily understand medical terms related to the article on Bone Marrow Transplantation ... Bone Marrow Transplantation - Animation. Animation and slides providing graphic explanation of Bone Marrow Transplantation (BMT ... Glossary for Bone Marrow or Hematopoietic Stem Cell Transplantation Do you wish to consult Oncologist for your problem? Ask ... Types of Bone Marrow Transplantation *Indications for Bone Marrow Transplantation *Complications of Bone Marrow Transplantation ...
We are recognized for our expertise in alternative donor transplantation; relapse prevention and treatment; transplantation for ... we offer the full range of blood and bone marrow stem cell transplantation options. ... Blood and Bone Marrow Stem Cell Transplantation. Wendy Stock, MD, is an expert in leukemia and stem cell transplantation. ... Birthplace of Bone Marrow Transplantation. In the late 1940s, University of Chicago researcher Dr. Leon Jacobson discovered ...
E. Donnall Thomas - Nobel Lecture: Bone Marrow Transplantation Past, Present and Future ...
... following bone marrow transplantation (BMT)?) and What is the mortality rate for myelodysplastic syndrome (MDS) following bone ... What is the mortality rate for myelodysplastic syndrome (MDS) following bone marrow transplantation (BMT)?. Updated: Jul 24, ... This bone marrow film (400× magnification) demonstrates an almost complete replacement of normal hematopoiesis by blasts in a ... Bone marrow film (1000× magnification) demonstrating ring sideroblasts in Prussian blue staining in a refractory anemia with ...
Procedure: Bone marrow transplantation Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a ... Non-Myeloablative Conditioning and Bone Marrow Transplantation. The safety and scientific validity of this study is the ... MedlinePlus related topics: Bone Marrow Transplantation Genetic and Rare Diseases Information Center resources: Sickle Cell ... Experimental: Non-Myeloablative Conditioning and Bone Marrow Transplantation Drug: Thymoglobulin Day 9 - 0.5 mg/kg IV before ...
Search of: ALEMTUZUMAB AND transplantation AND bone marrow - Modify Search. Expert Search ...
The month, day, and year a content piece was published electronically (as opposed to in print). Depending on the webpage, it may or may not be shown ...
Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more
Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.. Grochow LB1. ... High-dose busulfan is an important component of many bone marrow transplantation (BMT) preparative regimens. The dose-limiting ... Transplantation - Genetic Alliance. *Bone Marrow Transplantation - MedlinePlus Health Information. Miscellaneous. *BUSULFAN - ...
Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) ... Bone marrow transplantation shows potential for treating adults with sickle cell disease. The JAMA Network Journals ... Bone marrow transplantation shows potential for treating adults with sickle cell disease ... Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) ...
... a potentially lethal complication of bone marrow stem cell transplantation. CytoDyn is currently enrolling patients in a Phase ... 2 clinical trial with PRO 140 for the prevention of GvHD in leukemia patients undergoing BMSC transplantation. ... Monoclonal antibody prevents graft-vs-host disease in bone marrow transplantation model PRO 140 currently in phase 2 clinical ... Monoclonal antibody prevents graft-vs-host disease in bone marrow transplantation model. Bioscribe ...
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation. The recruitment status of this study is unknown. The ... For children undergoing bone marrow transplantation, respiratory failure carries mortality expectations well above 60%. The ... For children undergoing bone marrow transplantation, respiratory failure is a devastating complication, with mortality ... veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or ...
Focuses on bone marrow and stem cell transplantation. Definition of bone marrow transplantation; Comparison between allogeneic ... Bone marrow transplant. // Columbia Electronic Encyclopedia, 6th Edition;Q1 2017, p1 Bone marrow transplant: see bone marrow. ... Bone marrow transplant. // Columbia Electronic Encyclopedia, 6th Edition;Feb2013, p1 Bone marrow transplant: see bone marrow. ... Hematopoietic Reconstitution by Transplantation of Stem Cells from Bone Marrow or Blood. Singhal, Seema; Powles, Ray; Mehta, ...
Bone Marrow Transplantation. A bone marrow transplant is the process of replacing unhealthy HSC with healthy ones in order to ... What Is Bone Marrow?. Bone marrow is in the center of the bone and contains hematopoietic stem cells (HSC). These cells are ... How to become a bone marrow donor. Consider becoming a bone marrow donor and see if your HLA type could be a match for a sick ... When bone marrow is damaged or destroyed, it can no longer make normal blood cells and a stem cell transplant (bone marrow ...
  • A bone marrow donor is usually a close relative of the patient. (
  • Parallel studies of human bone marrow transplantation for malignancies by Mathe and colleagues focused on attempts to achieve GVT without fatal GVHD, but these were complicated by lack of sustainable engraftment of donor hematopoietic cells. (
  • Healthy bone marrow - from a donor whose tissue matches that of the patient, from the patient, or from umbilical cord blood - is then given via intravenous infusion. (
  • In the future, it can allow to abandon bone marrow transplantation and patients will no longer need to wait for suitable donor material. (
  • Bone marrow transplantation is uniquely curative for many patients with hematological malignancies due to the targeting of tumor cells by the transplanted donor immune system. (
  • We have developed several approaches for allogeneic transplantation with reduced intensity chemotherapy regimens in which anti-tumor effects are primarily mediated by donor immune cells. (
  • Paired donor exchange kidney transplantation is a process in which unrelated kidney donors are matched to recipients so that compatible transplants can be performed. (
  • Because only a small amount of bone marrow is removed, donating usually does not pose any significant problems for the donor. (
  • The area where the bone marrow was taken out may feel stiff or sore for a few days, and the donor may feel tired. (
  • After the successful bone marrow transplantation, the MHC molecules on cells derived from the donor bone marrow will match the haplotype expressed on the donor's kidney. (
  • Substantial progress has been made recently in the development of pre-treatment regimens that facilitate the sustained engraftment of donor marrow with reduced toxicity. (
  • We developed preclinical models of bone marrow transplantation (BMT) for MM using Vk*MYC myeloma-bearing recipient mice and donor mice that were myeloma naive or myeloma experienced to simulate autologous transplantation. (
  • While the center is best known for supplying blood products to hospitals, SBC's HLA lab supports the success of hundreds of bone marrow transplants administered at Stanford Health Care by providing and developing tests to determine donor and recipient organ compatibility. (
  • If bone marrow from a sibling is unavailable, the lab will search the National Marrow Donor Program registry for a match. (
  • Consider becoming a bone marrow donor and see if your HLA type could be a match for a sick patient. (
  • To find out how to become a donor or to learn more about bone marrow transplantation, visit Be the Match . (
  • Moreover, in our human cell therapy trials, donor osteoblast engraftment was demonstrated after transplantation of unmanipulated bone marrow ( 14 ), but the percentage of such engraftment could not be improved by transplanting as many as 5 × 10 6 isolated plastic-adherent marrow stromal cells per kg of body weight, a cell number that greatly exceeds the marrow stromal cell content of unmanipulated marrow ( 15 ). (
  • An image depicting bone marrow donor typing procedures can be seen below. (
  • Most bone marrow donor procedures are performed under general anesthesia. (
  • Adult Donor Allogeneic transplantation (a donor's stem cells are used, collected from either the blood of from the bone marrow). (
  • NewYork-Presbyterian participates in the National Marrow Donor Program providing us access to all available donors worldwide and enhancing your chances of finding an appropriate donor. (
  • If you are a candidate for bone marrow transplantation but do not have a matching donor, you may benefit from our experience performing this procedure using mismatched donors. (
  • Partial matches" have made bone marrow transplantation a possibility for people who may have a challenging time finding a matched donor, such as those from ethnic minority groups. (
  • A bone marrow transplant involves taking cells that are normally found in the bone marrow (stem cells), filtering those cells, and giving them back either to the donor (patient) or to another person. (
  • There are different types of bone marrow transplants depending on who the donor is. (
  • Stem cells are taken either by bone marrow harvest or apheresis from a genetically matched donor, usually a brother or sister. (
  • Unrelated bone marrow transplants (UBMT or MUD for matched unrelated donor). (
  • The genetically matched marrow or stem cells are from an unrelated donor. (
  • This leads to a state of mixed chimerism early after transplant where both recipient and donor HSC coexist in the bone marrow space. (
  • Allogeneic bone marrow transplantation involves two people, one is the (normal) donor and one is the (patient) recipient. (
  • In the case of a bone marrow transplant (BMT), the HSC are removed from a large bone of the donor, typically the pelvis, through a large needle that reaches the center of the bone. (
  • Our Mount Sinai bone marrow transplant specialists perform different types of BMT, and the right one depends on patient condition and availability of a compatible donor. (
  • Read about becoming a bone marrow donor . (
  • Bone marrow produces stem cells-unspecialized cells from the compatible donor-that renew by dividing into more cells that are specialized. (
  • We characterized the effect of transplanted donor mononuclear cells on relapse- and event-free survival after allogeneic bone marrow transplantation (BMT). (
  • In conclusion, content of donor DC2 cells was associated with decreased chronic graft-vs-host disease and graft-vs-leukemia effects consistent with Th2/Tc2 polarization of donor T cells following allogeneic bone marrow transplantation. (
  • The Allogeneic bone-marrow transplantation represents the only curative treatment and requires a compatible donor HLA. (
  • Fifteen patients received unmanipulated donor marrow cells and 29 patients received donor marrow cells depleted of lymphocytes ex vivo with the monoclonal antibody Campath-1. (
  • However, if this is not possible, for example, when a patient's blood marrow is not healthy, the bone marrow must come from a tissue-matched donor - this is called an allogenic transplant. (
  • In most allogenic transplants, the bone marrow is donated by a close relative, but sometimes the donor is an unrelated person who is a close genetic match to the patient. (
  • Matching donor and recipient tissue type is vital for the success of a bone marrow transplant. (
  • Normally, family members are the best source of compatible bone marrow tissue, but if a suitable donor is not found within the family , a suitable unrelated donor must be found. (
  • After a bone marrow transfusion, the recipient's blood group will change to that of the donor. (
  • The New Zealand Bone Marrow Donor Registry (NZBMDR) was formed in 1996. (
  • The NZBMDR is part of Bone Marrow Donors Worldwide - an organisation that helps patients around the world to find a compatible donor. (
  • By preventing the occurrence of GvHD, ATIR enables the use of a mismatched donor and consequently addresses a significant limitation in bone marrow transplantation , the timely availability of a donor. (
  • In this study the efficacy of ATIR(TM) will be investigated in patients diagnosed with AML, ALL or MDS eligible for an allogeneic bone marrow transplantation but for whom no matching donor is available. (
  • OBJECTIVES: I. Evaluate the incidence of acute graft versus host disease in patients undergoing transplantation with an unrelated or related matched or mismatched antigen donor. (
  • Bone marrow is harvested from patient's donor, depleted of T-cells, and infused. (
  • Patients undergo leukapheresis to collect white blood cells which are incubated with donor bone marrow cells in the presence of CTLA4-Ig for 36 hours. (
  • Icla da Silva Foundation non profit organization providing assistance to families with children suffering from leukemia, also a bone marrow donor recruitment group for the National Marrow Donor Program. (
  • As one of Hadassah University's senior scientists, Prof. Or continues to conduct research on various clinical topics, including the prevention of liver complications following bone marrow transplantation and immunotherapy using donor derived lymphocytes (immune cells) for the eradication of malignant diseases that would otherwise prove fatal. (
  • In December 2008 Prof. Or received the Menachem Begin Prize for his extensive medical and research work and for the establishment of two essential and life saving national projects: The unrelated volunteer bone marrow donor registry and the national public umbilical cord blood bank. (
  • In the cover story of the July issue of Cancer Biology & Therapy , Rangnekar and his team explore the transfer of bone marrow from Par-4/SAC-transgenic donor mice to control mice as a means of transferring anti-cancer potential. (
  • Intra-bone marrow-BMT (IBM-BMT) provides distinct advantages because it recruits donor-derived hematopoietic stem cells and mesenchymal stem cells. (
  • In animal experiments, intra-bone marrow-BMT (IBM-BMT) has been shown to efficiently recruit not only donor-derived hematopoietic stem cells (HSCs) but also mesenchymal stem cells (MSCs) [ 5 , 10 , 11 ]. (
  • An affiliate of the National Marrow Donor Program , our bone marrow transplant program is among the most accomplished and respected in the nation. (
  • Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation. (
  • It involves the administration of lymphohematopoietic cells after immunosuppressive chemotherapy or radiochemotherapy, to establish new donor-derived bone marrow and immune functions. (
  • Allogeneic BMT can be categorized by whether the donor cells were harvested from the bone marrow or obtained by apheresis of peripheral blood. (
  • As more donor T cells are collected with peripheral blood than bone marrow, most studies have shown GVHD to be increased. (
  • We report a case of cutaneous infection caused by Mycobacterium szulgai in a boy who underwent BMT with marrow from a matched unrelated donor. (
  • It is a relatively new method and can be as effective as Matched Unrelated Donor Transplantation in experienced centres. (
  • How is the donor determined in Matched Unrelated Donor Transplantation (MUD)? (
  • A very special method oftransplantation that is currently perfomrned in only a few centers worldwide is the Haploidentical stem cell transplantation .This methodis likely to eliminate the problem of finding a donor completely and therefore considered as the transplantation method of the future. (
  • 10/10 tissue match is not considered essential in Haploidentical transplantation, and the mother, father, semi-compatible sibling or the child of the patient can be a donor even if ther e is only half compatibility. (
  • A 16 year old man underwent an allogeneic bone marrow transplantation (BMT) from an HLA identical sibling donor for acute lymphoblastic leukaemia in 1984. (
  • Bone marrow transplants are necessary when marrow has been destroyed by drug or radiation therapy for cancer, often leukemia . (
  • Critical Link Discovered for Dangerous Complication of Stem Cell Transplants Transplant-associated thrombotic microangiopathy (TA-TMA) is a common and poorly recognized complication that can occur in about 30 percent of people receiving hematopoietic stem cell transplantation (HSCT). (
  • Bone marrow is the traditional source of stem cells for both autologous and homologous transplants. (
  • Bone-marrow transplants can benefit patients with leukemia, lymphoma, myeloma or aplastic anemia. (
  • Patients with other types of cancers such as breast cancer, ovarian cancer, advanced testicular cancer, sarcoma and low-grade lymphoma also are sometimes treated with bone-marrow transplants. (
  • Certain genetic diseases of the blood (e.g. thalassemia, sickle-cell disease, severe combined immunodeficiency, among others) also are sometimes treated with bone-marrow transplants. (
  • Our care teams perform more than 200 stem cell transplants a year and we perform more allogeneic transplants (transplants using bone marrow or stem cells from donors) for older adults than any other center in the tri-state area. (
  • Bone marrow transplants may also be needed if the bone marrow has been destroyed by a disease. (
  • The risks and benefits must be weighed in a thorough discussion with your healthcare provider and specialists in bone marrow transplants before the procedure. (
  • What are the different types of bone marrow transplants? (
  • Other patients who receive bone marrow transplants include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia and was born with defective stem cells. (
  • Other conditions that bone marrow transplants are considered for include thalassemia major, sickle cell disease, myelodysplastic syndrome, lymphoma, and multiple myeloma. (
  • The Bone Marrow Transplant Program at Mount Sinai Health System has been at the forefront of the field in treating hematological malignancies with bone marrow transplants (BMT). (
  • Learn more about bone marrow transplants . (
  • In fact, bone marrow transplants are the first example of a successful stem cell therapy and have been used to treat people with life threatening blood diseases since the 1950s. (
  • When were bone marrow transplants first used? (
  • Bone marrow transplants are now used worldwide and are a prime example of a successful stem cell therapy. (
  • Find out more about the history of bone marrow transplants in this timeline . (
  • This includes sections on the function of marrow, types of transplants, procedures, side effects, and a list of other resources. (
  • Professor Reuven Or and his staff established the Transplantation Center and were early leaders in performing bone marrow transplants, originally in children and later in adults. (
  • In 1986 the first transplants were done by the removal of the bone marrow components which caused significant graft-versus-host complications. (
  • Ankeny DP, McTigue DM, Jakeman LB (2004) Bone marrow transplants provide tissue protection and directional guidance for axons after contusive spinal cord injury in rats. (
  • Thanks to ongoing medical research, bone marrow transplants have become an effective therapeutic approach to treat certain cancers and blood disorders. (
  • Since 1985, 67 patients have received conditioning of Bu and Cy for HLA-identical sibling bone marrow transplants. (
  • Read "From Small-town House Calls to Bone Marrow Transplants, Nobel Laureate Continues Father's Legacy" in this special anniversary edition of the ASCO Post . (
  • In 2017, the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recognized by the Center for International Blood and Marrow Transplant Research as one of 13 centers in the U.S. that exceeded expectations for one-year survival rates for patients receiving blood stem cell transplants from healthy donors. (
  • Details how the factors that drove clinical use of high-dose chemotherapy with autologous bone marrow transplantation (HDC/ABMT)-patient demand, physician enthusiasm, media reporting, litigation, and administrative mandates-converged to propel the procedure forward despite a lack of proven clinical effectiveness. (
  • First, high doses of radiation and/or chemotherapy are used to destroy abnormal bone marrow. (
  • Bone marrow transplantation restores stem cells that were destroyed by high doses of chemotherapy and/or radiation therapy. (
  • The development of nonmyeloablative conditioning regimens (use of lower doses of chemotherapy or radiation to prepare the bone marrow to receive new cells) may facilitate safer application of allogeneic HSCT to eligible adults, according to background information in the article. (
  • Allogeneic transplantation is not indicated in first complete remission for patients with low cytogenetic risk, and it appears that allogeneic transplantation, autologous transplantation, and consolidation chemotherapy are equivalent for patients with intermediate risk. (
  • In a bone-marrow transplant, the patient is treated with very high doses of chemotherapy, with or without radiation, to destroy cancer cells. (
  • When the doses of chemotherapy or radiation needed to cure a cancer are so high that a person's bone marrow stem cells will be permanently damaged or destroyed by the treatment, a bone marrow transplant may be needed. (
  • Replace the bone marrow and restore its normal function after high doses of chemotherapy and/or radiation are given to treat a malignancy. (
  • Non-myeloablative allogeneic HSCT is a newer treatment approach which uses lower doses of chemotherapy and radiation which are too low to erradicate all of the bone marrow cells of a recipient. (
  • Before transplantation , the patient is given high doses of chemotherapy or radiation to destroy their own cancerous or abnormal blood cells. (
  • In most cases, doctors give the compounds in conjunction with an autologous bone marrow transplantation , removing a sample of the patient's marrow before chemotherapy, then reinfusing it with CSFs to quickly "reseed" the marrow and blood supply with new white blood cells. (
  • Three regimens for bone marrow transplant were used: 74 patients received single-dose, total-body irradiation (TBI), 90 patients received fractionated TBI, and 33 received chemotherapy alone. (
  • Autologous Peripheral Stem Cell Transplantation following High Dose Chemotherapy (N.E. Ontario Regional Cancer Center, Canada) FAQ, research history, and progress with PBSC, including a phase III clinical trial run at the center. (
  • Before bone marrow transplantation, the patient will be given chemotherapy treatment. (
  • For new stem cells to form in bone marrow after chemotherapy it takes 4 weeks time. (
  • The physician will decide the type of treatment, set a treatment plan for before transplantation, and use chemotherapy and/or radiation in the preparation process. (
  • After the chemotherapy and/or radiation, the peripheral stem cell transplantation will be administered. (
  • The LyMa-101 trial achieved its primary endpoint and showed the potential activity of obinutuzumab plus [dexamethasone, high-dose cytarabine and cisplatin] as induction chemotherapy , with bone marrow minimal residual disease negativity potentially predicting long-term disease control," the study authors wrote. (
  • When Thomas came to Seattle in 1963, his team at the University of Washington sought to use radiation and chemotherapy to destroy a patient's diseased bone marrow and then replace it with new marrow from a healthy patient. (
  • In addition to complications seen from exposure to chemotherapy and radiation, patients undergoing allogeneic transplantation can experience unique late effects secondary to graft versus host disease (GVHD) and autoimmunity. (
  • Bone marrow transplantation can be a life-saving method in Acute Leukemias and Lymphomas which are resistent to standard chemotherapy. (
  • Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose? (
  • Allogeneic blood and marrow transplantation (BMT) (also often called stem cell or hematopoietic cell transplantation) is the treatment of choice for many blood diseases, both malignant and non-malignant. (
  • Lymphocytes are critically important components of the graft from both efficacy and toxicity standpoints, and so "stem cell" and "hematopoietic cell" transplantation are really misnomers. (
  • To stimulate and facilitate further research, the NCI and NHLBI held the First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation on April 28 and 29, 2011. (
  • Patients with an acute leukemia often present with signs and symptoms of bone marrow failure, such as fatigue and pallor, fever, infection and/or bleeding with purpura and petechiae. (
  • Bone marrow transplantation (or stem cell transplantation) is a well-established procedure for patients with relapsed or high-risk cancers of the blood, such as leukaemia , lymphoma and myeloma . (
  • Our patients see physicians who are experts not only in transplantation but also in the patient's specific cancer or blood disease, such as leukemia, lymphoma and multiple myeloma. (
  • Select patients are candidates for outpatient stem cell transplantation, an approach that offers the full benefits of this life-saving treatment while allowing the patient to spend nights in the comfort of their own home. (
  • Relapse remains the biggest challenge for cancer patients who have undergone stem cell transplantation. (
  • Preliminary results of non-myeloablative allogeneic stem cell transplantation suggest that the procedure can be performed in patients who are ineligible for myeloablative alloBMT, and that sustained remissions of several hematologic malignancies can be obtained. (
  • Bone marrow transplantation (BMT) is considered, at present, an appropriate therapy for MPS II subjects without severe neuropsychological impairment, however molecular analysis in BMT treated patients has been poorly studied. (
  • Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA . (
  • CytoDyn is currently enrolling patients in a Phase 2 clinical trial with PRO 140 for the prevention of GvHD in leukemia patients undergoing BMSC transplantation. (
  • GvHD is a serious complication that limits the use of BMSC transplantation in patients with blood cancers. (
  • The potential of PRO 140 to prevent this life-threatening condition could help extend the use of BMSC transplantation, an important and effective therapy, to more patients. (
  • Graft-versus-host disease is a risk when patients receive bone marrow stem cells donated from another person. (
  • Transplantation with autologous hematopoietic progenitors remains an important consolidation treatment for patients with multiple myeloma (MM) and is thought to prolong the disease plateau phase by providing intensive cytoreduction. (
  • Respiratory failure requiring orotracheal intubation (OTI) and mechanical ventilation (MV) is almost always a fatal complication in patients who undergo hematopoietic progenitor transplantation (HPT). (
  • Eosinophilic pulmonary syndrome as a manifestation of GVHD following hematopoietic stem cell transplantation in three patients. (
  • We report the occurrence of eosinophilic pulmonary syndrome in three patients following allogeneic hematopoietic stem cell transplantation (HSCT), and postulate that this entity is part. (
  • There is a consensus on the indication of allogeneic transplantation with myeloablative conditioning for patients presenting cytogenetic changes considered high risk. (
  • Orthotopic liver transplantation (OLT) is the treatment of choice for acute or chronic liver failure but is limited by general organ shortage, leading to increased mortality among patients on the waiting list. (
  • DALLAS - November 4, 1998 - UT Southwestern Medical Center at Dallas has inaugurated a new bone-marrow transplantation program, which will provide potentially life-saving therapies to patients with some forms of cancer. (
  • We have advanced, dedicated bone marrow transplant units offering personal monitoring and special airflow systems for patients with weakened immune systems. (
  • Bone marrow transplant (BMT) is a special therapy for patients with certain cancers or other diseases. (
  • However, patients experience diseases differently, and bone marrow transplant may not be right for everyone who suffers from these diseases. (
  • Pulmonary function was measured before and at intervals after treatment in 44 patients who received a bone marrow transplant for chronic myeloid leukaemia in the chronic phase. (
  • Carbon monoxide transfer factor--TLCO) was under 75% of predicted normal in nine patients before transplantation. (
  • It is considered that most patients who survive the short term risks of bone marrow transplant have only minor long term impairment of pulmonary function. (
  • For patients with severe disorders of the blood, like leukaemia , a bone marrow stem cell transplant is often the only possible treatment. (
  • The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. (
  • Our findings indicate that bone marrow transplantation can cure sickle cell disease in a significant number of patients with advanced disease,'' said Dr. (
  • Patients undergo an allogenic bone marrow transplantation on day 0. (
  • OBJECTIVES: I. Determine the incidence and severity of acute graft versus host disease after transplantation of HLA haploidentical bone marrow preincubated with alloantigen and CTLA4-Ig ex vivo in patients with hematologic malignancies. (
  • Patients with acute lymphocytic leukemia, prior lymphoid blast crisis chronic myelogenous leukemia, high grade non-Hodgkin's leukemia (NHL), intermediate grade NHL with prior marrow or extramedullary disease, or prior CNS leukemia receive 2 doses of methotrexate intrathecally prior to bone marrow transplantation, and 4-6 doses following. (
  • 197 patients treated with allogeneic or autologous bone marrow grafts at least 180 days before the start of the study. (
  • Bone Marrow Transplant Support Group (Ireland) Funded in 1994 to provide support for Bone Marrow Transplant patients and their families. (
  • Fifty-nine patients who ranged in age from 3.3 to 15.9 years (median, 10.1 years) received HLA-identical sibling marrow allografts between September 1991 and April 2000. (
  • Fifty-five patients survive, and 50 survive free from sickle cell disease, with a median follow-up of 42.2 months (range, 11.8 to 115 months) after transplantation. (
  • or =6 months after transplantation in peripheral blood, varied between 90% and 99% in 8 patients. (
  • None of the patients have experienced painful events or other clinical complications related to sickle cell disease after transplantation. (
  • These observations strongly suggest that patients with sickle cell disease who develop persistent mixed hematopoietic chimerism after transplantation experience a significant ameliorative effect. (
  • Such healthy stem cells will be collected from patients bone marrow, patients close relatives, or from donors and injected into the blood of the patient. (
  • In this transplantation, stem cells collected from donors will be injected into patients blood intravenously. (
  • This longitudinal study sought to identify predictors of posttraumatic growth among cancer patients (N=72) undergoing bone marrow transplantation. (
  • The department treats patients of all ages who are in need of bone marrow transplantation. (
  • In addition to his other responsibilities Prof. Or heads up the Ambulatory Therapy Center which treats patients after transplantation. (
  • At present there are no therapies which improve outcome in patients after injury, but stem cell or reparative cell transplantations are a promising avenue which needs further evaluation at laboratory and translational level. (
  • To answer this question, we studied allogeneic bone marrow and stem-cell transplantation for patients with advanced CLL [2, 3] who failed to respond to fludarabine, an agent considered by many to be the most effective conventional treatment for CLL. (
  • Our pediatric bone marrow transplant experts at University Hospitals Rainbow Babies & Children's provide highly personalized care to young patients who require the most advanced diagnostic tools and treatment approaches. (
  • Our young patients also benefit from the latest clinical research and advanced medicine for bone marrow transplantation. (
  • Our 100-day patient survival rate for bone marrow transplant patients exceeds 96 percent. (
  • 4 Therefore, we performed a randomized controlled trial to assess the functional effect of direct intramyocardial injection of autologous bone marrow cells on left ventricular ejection fraction (LVEF) in patients with a chronic myocardial infarction undergoing coronary artery bypass graft (CABG) surgery. (
  • Patients were randomly allocated in a 1:1 ratio to either the control, conventional CABG, or bone marrow cell (BMC) group, by means of sequentially numbered sealed envelopes. (
  • A treatment regimen with Gazyva (obinutuzumab) plus dexamethasone, high-dose cytarabine and cisplatin was well tolerated in patients with mantle cell lymphoma who were eligible for bone marrow transplantation, according to study results published in Lancet Haematology . (
  • Throughout this trial, 95% of patients completed the induction phase, 86% underwent autologous stem cell transplantation and 81% of patients started the maintenance phase. (
  • Of the 73 patients within the efficacy set, which was the group of patients with measured minimal residual disease, 55% achieved minimal residual disease negativity within bone marrow after completion of the induction phase. (
  • Of these patients who were minimal residual disease positive, 12 patients tested positive in bone marrow, two patients had disease progression and four patients did not undergo minimal residual disease assessment. (
  • Bone marrow transplantation is increasingly being utilized as part of a therapeutic modality in the treatment of cancer patients. (
  • Transplantation patients are at such a particularly high risk of developing a wide variety of different types of infection, that they inevitably can serve as an excellent framework for discussion of all the types of infections that occur during the treatment of cancer. (
  • CONCLUSIONS Transplantation of UC-MSC and aBM-MNC was safe and associated with moderate improvement of metabolic measures in patients with established T1D. (
  • [ 7 ] of 798 patients who survived more than 5 years after transplantation, 328 were children. (
  • [ 2 , 8 ] Survivors of bone marrow transplantation were more likely to have a severe or life threatening condition (relative risk [RR] = 3.9), more than one chronic condition (RR = 2.6), functional impairment (RR=3.5), and activity limitations (RR = 5.8) than conventionally treated patients. (
  • The present study evaluated the safety and preliminary efficacy of transendocardial transplantation of autologous bone marrow MSCs in patients with severe chronic heart failure. (
  • Three patients did not receive cell transplantation because of insufficient cell expansion, an episode of pulmonary edema related to baseline catheterization and bone marrow aspiration, or acute colitis unrelated to the study procedure. (
  • This method of transplantation is mainly used in Multiple Myeloma and Lymphoma patients. (
  • Performed for patients who do not have a full matchde sibling and in urgent need of transplantation. (
  • The study quantified sCD27 levels and assessed the presence of oligoclonal IgG bands in CSF samples of secondary progressive patients with MS treated by autologous bone-marrow transplantation. (
  • T cell production and immune recovery is also slow and incomplete after bone marrow transplantation in older patients. (
  • By combining total body irradiation (TBI) with infusion of allogeneic bone marrow, Thomas's group in 1959 demonstrated the first leukemia cure by HSCT [ 4 ]. (
  • They were prepared for marrow transplantation with fractionated total body irradiation (3× 4 Gy) and cyclophosphamide (2× 60 mg/kg). (
  • These so-called myeloablative conditioning regimens most commonly use the marrow-toxic agents busulfan or total body irradiation (TBI), usually in combination with high-dose cyclophosphamide. (
  • An immunological syndrome featuring transverse myelitis, Evans syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia. (
  • A patient with severe aplastic anemia underwent a matched unrelated bone marrow transplant, following which he developed a complex autoimmune syndrome. (
  • NewYork-Presbyterian offers bone marrow and stem cell transplantation for people with hematological malignancies (e.g., leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS)) for myeloproliferative disorders such as myelofibrosis, for AL-amyloidosis, and for non-malignant blood disorders such as severe aplastic anemia and sickle cell anemia (SCA). (
  • Bone marrow transplant has been used successfully to treat diseases such as leukemias, lymphomas, aplastic anemia, immune deficiency disorders, and some solid tumor cancers since 1968. (
  • Replace diseased, nonfunctioning bone marrow with healthy functioning bone marrow (for conditions such as leukemia, aplastic anemia, and sickle cell anemia). (
  • Stem cell transplantation , also known as bone marrow transplantation, is used to treat blood diseases such as aplastic anemia, bone marrow failure, and blood cancers, as well as to restore blood-forming cells in the body. (
  • Georges GE, Storb R. Stem cell transplantation for aplastic anemia. (
  • Bone marrow transplantation (BMT) is a powerful strategy for the treatment of leukemia, aplastic anemia, congenital immunodeficiency and autoimmune diseases. (
  • METHODS: We reviewed the medical records, bone marrow and liver biopsies of 7 children with severe hepatitis, with or without liver failure, who subsequently had developed aplastic anaemia. (
  • Bone marrow transplantation is performed in individuals who have diseases affecting the bone marrow such as leukemia or myelodysplastic syndrome, other hematological malignancies such as Lymphomas and Multiple Myeloma, Aplastic anemia where the bone marrow cannot provide adequate blood-forming cells. (
  • In some cases, the patient will receive an autologous transplant where the stem cells come from the patient's own blood or bone marrow, which would need to have been drawn and stored prior to the patient becoming ill. (
  • the donated bone-marrow cells grow and repopulate the patient's blood cells. (
  • Autologous bone marrow transplantation involves isolation of HSC from a patient, storage of the stem cells in a freezer, medical treatment of the patient that destroys stem cells remaining in the body, and return of the patient's own stored stem cells to their body. (
  • This is possible in the case of certain diseases that do not affect the patient's bone marrow so the doctor can use the patient's healthy cells for the transplant. (
  • There are various potential side effects associated with transplantation, these will largely depend on how well matched the donor's cells are to the patient's cells. (
  • Stem cells from bone marrow are collected and will be introduced into the patient's blood intravenously. (
  • In this transplantation, stem cells collected from the patient's bone marrow are introduced into the same patient's blood. (
  • Every year individuals receive hematopoietic stem cell transplantation (HSCT) to eradicate malignant and nonmalignant disease. (
  • AML is currently the most common indication for hematopoietic stem cell transplantation (HSCT) worldwide (8) . (
  • Bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) is a medical procedure in the field of hematology and oncology that involves transplantation of hematopoietic stem cells (HSC). (
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (
  • Likewise, many children are now surviving hematopoietic stem-cell transplantation (HSCT) (see related histology slide below) and require structured long-term follow-up care. (
  • Age-related differences in thymic function influence the rapidity of T cell reconstitution following hematopoietic stem cell transplantation (HSCT). (
  • Sergio Giralt, Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center, talks about bone marrow transplantation for the treatment of leukemia . (
  • Animation and slides providing graphic explanation of Bone Marrow Transplantation (BMT)/Stem Cell Transplantation that is done for leukemia and other blood-related disorders. (
  • The healthy, transplanted stem cells can restore the bone marrow's ability to produce the blood cells the patient needs.In some types of leukemia, the graft-versus-tumor (GVT) effect that occurs after allogeneic BMT is crucial to the effectiveness of the treatment. (
  • Wendy Stock, MD, is an expert in leukemia and stem cell transplantation. (
  • This report aims to define guidelines for the indication of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia in Brazil. (
  • This report on the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia was presented to and ratified by the Brazilian Bone Marrow Transplantation Society at the meeting on the Brazilian Guidelines for hematopoietic stem cell transplantation. (
  • Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. (
  • aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Bone Marrow Transplantation and Leukemia. (
  • Also, high quality research contributions describing original and unpublished results of conceptual, constructive, empirical, experimental, or theoretical work in all areas of Bone Marrow Transplantation and Leukemia are cordially invited for presentation at the conference. (
  • ICBMTL 2021 has teamed up with the Special Journal Issue on Bone Marrow Transplantation and Leukemia . (
  • I'm Having a Bone Marrow Transplant (Leukemia and Lymphoma Society, USA) a coloring book designed to help children up to 15 years of age express themselves throughout the stressful process of having a bone marrow transplant. (
  • Laurel Simmons' Home Page (BMT / Leukemia info) Laurel had a bone marrow transplant in 1987 for CML. (
  • Bone marrow transplantation (BMT) is a powerful strategy for the treatment of hematologic disorders, including leukemia and autoimmune diseases [ 1 - 3 ]. (
  • The patient achieved complete remission by an induction therapy for acute lymphoblastic leukemia, underwent allogeneic bone marrow transplantation, and has remained in complete remission for more than 3 years. (
  • Led by Dr. E. Donnall Thomas, Fred Hutch scientists pioneered the development of bone marrow transplantation to treat leukemia and other blood cancers. (
  • Performed for many years in humans diagnosed with lymphoma, leukemia and other life-threatening blood diseases, bone marrow transplantation has boosted survival rates to 85 percent for some cancers. (
  • A bone marrow transplant is a procedure that replaces a person's faulty bone marrow stem cells. (
  • Bone marrow transplantation is a medical procedure to replenish bone marrow - the soft tissue within bones that produces new blood cells. (
  • In general, the procedure for obtaining bone marrow, which is called "harvesting," is similar for all three types of BMTs (autologous, syngeneic, and allogeneic). (
  • The most serious risk associated with donating bone marrow involves the use of anesthesia during the procedure. (
  • receipt of hematopoietic stem cells "bone marrow" from another individual) is curative for children with severe sickle cell disease, but associated toxicity has made the procedure prohibitive for adults. (
  • Optimization of the bone marrow transplantation procedure using stem cells that are genetically modified to systemically secrete potent protein payloads of Par-4/SAC killer activity may offer a new approach to treat not only primary tumors but also metastatic tumors of diverse origin. (
  • Autologous transplantation is the procedure of using the person's own stem cells. (
  • Full Matched Allogenic transplantation is the procedure of using another person's fully compatible stem cells. (
  • However, uncertainty exists whether the efficacy of BMSCs after intraspinal transplantation justifies an invasive procedure. (
  • If they are not available, donors may also be found in national and international bone marrow registries. (
  • Marrow donors may suffer from complications like pain and discomfort at the site of injection. (
  • Donors administered growth factors prior to harvesting could sometimes undergo complications like bone pain and splenic rupture. (
  • The lack of suitable donors continues to be a limit to access to transplantation. (
  • A buccal swab can be used for human leukocyte antigen (HLA) typing of bone marrow donors. (
  • Buccal swabs are typically obtained at the time of bone marrow registry enrollment for all potential donors. (
  • Unrelated donors are found through national bone marrow registries. (
  • Allogeneic bone marrow transplantation, as we understood it, allows saving lives, but cannot take place without donors. (
  • After transplantation, the researchers discovered the expression of cancer-killer SAC-GFP activity in bone marrow cells of the recipient mice, implying the successful transfer and colonization of the anti-cancer tissue from the donors. (
  • The preliminary search is a computerized search designed to identify potential bone marrow donors that have similar HLA antigens. (
  • Finally, in 1965, Mathe's group reported a case of successful long-term engraftment without GVHD after allogeneic bone marrow transplantation [ 5 ]. (
  • Nearly 50 years later, GVHD and graft rejection continue to limit the curative application of allogeneic bone marrow transplantation (BMT), both for malignant and nonmalignant hematologic conditions. (
  • VANCOUVER, WASHINGTON (November 14, 2017) - Newly published research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc. (OTC.QB: CYDY), to effectively block the development of graft-versus-host disease (GvHD), a potentially lethal complication of bone marrow stem cell (BMSC) transplantation. (
  • This research provided CytoDyn with strong rationale for exploring the use of PRO 140 in its second clinical indication, the prevention of GvHD in BMSC transplantation, following our focus on the treatment of HIV infection," said Dr. Burger. (
  • GVHD amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naive T cell populations. (
  • Overall, survival is probably similar with both bone marrow and peripheral blood grafts, with the higher toxicity and improved tumor control associated with GVHD offsetting each other. (
  • Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? (
  • Examples of pulmonary complications that are associated with allogeneic bone. (
  • Our scientists are developing new approaches to lower your risk of treatment-related complications and to reduce the chance that your cancer will come back after transplantation. (
  • If one of the brothers and sisters is compatible, we speak about geno-identical allogeneic transplantation having the advantage of reducing the complications post-transplantation. (
  • Background and Purpose -There is only limited information about late neurological complications after bone marrow transplantation (BMT). (
  • There were no periprocedual complications such as sustained ventricular arrhythmias and pericardial effusions, nor did any significant adverse effects such as bone formation in the myocardium at the 2-month follow-up. (
  • A fundamental mission of the Hematological Malignancies and Bone Marrow Transplantation program is to enhance our understanding of the basic biology of blood cancers and to translate this knowledge towards the development of effective therapies. (
  • While it is appropriate to treat transfusional iron overload to limit end-organ injury after bone marrow transplantation (BMT) for beta-thalassemia major (TM), this approach after BMT for sickle cell disease (SCD) and hematological malignancies has not been studied. (
  • We are pleased to have someone with Dr. Collins' experience develop and direct the new bone-marrow transplant program," said Dr. Richard Gaynor, interim director of the Harold C. Simmons Comprehensive Cancer Center. (
  • Universityof Minnesota : Bone Marrow Transplant Program (USA) This site includes details of the BMT program, research, staff, and support services. (
  • This means the UH pediatric bone marrow transplant program exceeds national standards in patient care, laboratory practices and patient outcomes. (
  • The bone marrow transplant program offers extraordinary outcomes. (
  • This groundbreaking work influenced many scientists investigating bone marrow transplant for humans, including the winner of the 1990 Nobel Prize in Physiology or Medicine. (
  • 1 , 2 ] demonstrated that the infusion of allogeneic bone marrow cells may destroy recipient tumor cells, indicating the possibility of cytotherapeutic antitumor potential in the transplanted allogeneic cellular graft (graft-versus-tumor activity, GVT). (
  • Presents a case report on a 52-year-old male with severe gastrointestinal graft-versus-host disease who developed dyspnea and irreversible airflow obstruction following allogeneic bone marrow stem cell transplantation. (
  • ABSTRACT: The graft-vs-tumor effect is an important part of the curative potential of allogeneic transplantation. (
  • 1-7] A number of factors, including patient disease status, age, conditioning regimen, and (for allogeneic recipients) type of graft-vs-host disease prophylaxis, influence the probability of survival after transplantation. (
  • A variety of studies support the role of larger numbers of CD34-positive cells in the graft in faster hematopoietic reconstitution after autologous and allogeneic transplantation. (
  • 11,16] Recipients of T-cell-depleted bone marrow allografts have a decreased risk of developing graft-vs-host disease,[17,18] but experience delayed immune reconstitution and have an increased risk of infections, graft failure, and relapse. (
  • I am particularly excited to work on the ATIR(TM) product, which is aimed at preventing acute Graft versus Host Disease and thus enables severe mismatched bone marrow transplantation (so-called 'haplo-identical transplantation') and is entering a pivotal study in early 2009", says Maarten Egeler. (
  • Doctors prefer Autologous bone marrow transplantation as the stem cells are derived from the same patient or his family members which do not pose rejection, graft versus host cell reactions. (
  • In this randomized trial, we assessed the hypothesis that direct intramyocardial injection of autologous mononuclear bone marrow cells during coronary artery bypass graft (CABG) could improve global and regional left ventricular ejection fraction (LVEF) at 4-month follow-up. (
  • The paper highlights the pre-clinical research and demonstrates that engraftment is robust following transplantation of treated graft, and the graft retains its immune reconstitution and anti-leukemic effects. (
  • Although reports of multilineage engraftment by a single marrow-derived stem cell support this idea, more recent evidence has challenged claims of stem cell transdifferentiation and therefore the existence of a multipotent hematopoietic/osteogenic progenitor cell. (
  • Pilot studies of autologous stem cell transplantation using peripheral blood have demonstrated rapid engraftment with this technique. (
  • Evaluate the rapidity of engraftment and CD4 count recovery post-transplantation in this patient population. (
  • Myeloablative (MyA) bone marrow transplantation (BMT) results in robust engraftment of BMT-derived cells in the central nervous system (CNS) and is neuroprotective in diverse experimental models of neurodegenerative diseases of the brain and retina. (
  • In adults, thymic reconstitution is delayed until after marrow engraftment is established, and is significantly improved by approaches that increase marrow chimerism, such as pre-transplant irradiation. (
  • In contrast, we show that neonatal mice undergo more rapid and efficient thymic reconstitution than adults, even when bone marrow engraftment is minimal and in the absence of pre-transplant radiation. (
  • Allogeneic blood or marrow transplantation (alloBMT) is a curative therapy for a variety of hematologic disorders, including sickle cell disease and thalassemia. (
  • This capacity may solely reflect the activities of multiple discrete stem cells with restricted genetic programs, such as hematopoietic stem cells able to differentiate to leukocytes, erythrocytes, or megakaryocytes and mesenchymal stem cells that can differentiate to bone, cartilage, or adipose tissue ( 3 ). (
  • One interpretation of these observations is that cells other than those in the adherent population, where mesenchymal stem cells are thought to reside ( 3 ), are potent transplantable progenitors of osteoblasts, consistent with laboratory studies showing that nonadherent cells can give rise to bone ( 12 , 13 , 16 ). (
  • BM-HSC: bone marrow derived hematopoietic stem cell, hepatic SC: hepatic stem cell, MSC: mesenchymal stem cell. (
  • Baddoo M, Hill K, Wilkinson R, Gaupp D, Hughes C, Kopen GC, Phinney DG (2003) Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. (
  • Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implication for cell therapy of bone. (
  • One report has suggested the potential of mesenchymal stoma cells as a novel cell therapy to prevent allograft rejection and interstitial fibrosis/ tubular atrophy after kidney transplantation [ 12 ]. (
  • OBJECTIVE To determine the safety and effects on insulin secretion of umbilical cord (UC) mesenchymal stromal cells (MSCs) plus autologous bone marrow mononuclear cell (aBM-MNC) stem cell transplantation (SCT) without immunotherapy in established type 1 diabetes (T1D). (
  • Experimental studies have shown that transplantation of mesenchymal stem cells (MSCs) improves cardiac function in heart failure. (
  • Bone marrow cells were cultured in medium containing 15% auto serum for 3 weeks to expand adherent fibroblastic cells (MSCs), of which surface antigen expression was mesenchymal type. (
  • Features peer-reviewed articles covering all aspects of clinical and basic hemopoietic stem cell transplantation. (
  • The Adult Hematopoietic Stem Cell Transplantation Fellowship Program at Memorial Sloan Kettering Cancer Center is an independent, one-year program designed to prepare physicians for academic careers in Stem Cell Transplantation, including experience with clinical research. (
  • The program in Bone Marrow Transplantation (Drs. David E. Avigan, Jon Arnason, Vassiliki Boussiotis, Robin M. Joyce, James D. Levine, Jacalyn Rosenblatt, Dimitrios Tzachanis, and Jeffrey I. Zwicker) is largely involved with clinical and translational research activities. (
  • These data provide new insights into the mechanisms of action of transplantation in myeloma and provide rational approaches to improving clinical outcomes. (
  • A number of clinical trials have proved the superiority of this method over collection from the bone marrow. (
  • Current data suggest, that in human orthotopic liver transplantation, liver regeneration by BM-HSC is a rather rare event and therefore not of clinical relevance. (
  • Many basic scientists here are interested in clinical transplantation. (
  • You may have the opportunity to participate in a clinical trial studying new, safer methods of preparing for, receiving, and recovering from a bone marrow transplant. (
  • We report the first successful allogeneic bone marrow transplant (allo-BMT) for AL amyloidosis, which after 3 years was associated with complete clinical recovery. (
  • On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. (
  • The scope of the journal includes stem cell biology, transplantation immunology, translational research, and clinical results of specific transplant protocols. (
  • Bone Marrow Transplantation is abstracted and indexed in BIOBASE/Current Awareness in Biological Sciences, BIOSIS, Current Contents/Clinical Medicine, Current Contents/Life Sciences, EMBASE/Excerpta Medica, MEDLINE/Index Medicus, and Science Citation Index. (
  • Here we review the perfusion method (for harvesting BMCs) and IBM-BMT (for their transplantation) and show that this combination will become a powerful new clinical strategy for allogeneic BMT. (
  • Clinical examination revealed a retroperitoneal bulky tumor, a breast tumor, and lymphoblasts in bone marrow. (
  • 1 Based on those data, 2 clinical trials have shown that intracoronary infusion of autologous bone marrow cells improves left ventricular functional recovery after acute myocardial infarction and successful percutaneous coronary intervention. (
  • The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment. (
  • Promising results in the experimental and clinical settings support the use of stem cell transplantation (SCT) or bone marrow (BM)-derived hematopoietic stem cells (HSCs) for the treatment of autoimmune diabetes ( 5 - 10 ). (
  • An infection of a bone is called osteomyelitis. (
  • Bone marrow was flushed from the dissected femurs and tibias of FVB/N mice (The Jackson Laboratory), and the isolated adherent marrow cells were transduced with a GFP-expressing retroviral vector (multiplicity of infection, ≈5) as described ( 17 ). (
  • Infection is the major problem with allogeneic bone marrow transplantation. (
  • The patient undergoing allogeneic bone marrow transplantation is at particularly high risk of infection due to the major perturbations of host defenses, which include granulo- cytopenia, cellular immune dysfunction, humoral immune dysfunction, blood product transfusions, and vascular access devices. (
  • These stem cells reproduce into mature, functioning blood cells quicker and more effectively than do stem cells taken from the bone marrow of another child or adult. (
  • Hematopoietic stem cells (HSCs) are very rare cells, representing approximately one in 100,000 bone marrow (BM) cells in the adult. (
  • Did you know that bone marrow contains adult stem cells? (
  • RESEARCH DESIGN AND METHODS- MSCs were isolated from bone marrow of adult rats and transplanted into hind limb skeletal muscles of rats with an 8-week duration of streptozotocin (STZ)-induced diabetes or age-matched normal rats by unilateral intramuscular injection. (
  • Methods and Results- Immediately after hindlimb ischemia was created, rats were randomized to receive AM infusion plus bone marrow-derived mononuclear cell (MNC) transplantation (AM+MNC group), AM infusion alone (AM group), MNC transplantation alone (MNC group), or vehicle infusion (control group). (
  • Bone marrow-derived mononuclear cells (MNCs) include a variety of stem and progenitor cells, such as endothelial progenitor cells (EPCs), and contribute to pathological neovascularization. (
  • Acute homing of bone marrow-derived mononuclear cells in intramyocardial vs. intracoronary transplantation. (
  • DESIGN: Eight pigs were randomized to receiving autologous purified (111)indium-labeled bone marrow mononuclear cells (BMMCs) (10(8) cells/2 ml) by intramyocardial (IM) (n=4) or by intracoronary (IC) (n=4) transplantation after 90 minutes occlusion of the CX-coronary artery. (
  • The Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's is an international leader in delivering cutting-edge therapies for many diseases such as refractory, or hard-to-treat, cancers, rare genetic conditions affecting the immune system, hemoglobinopathies and bone marrow failure syndromes. (
  • Stem cell transplant (also known as bone marrow transplant or BMT) is an established treatment for many cancers and blood diseases once considered incurable. (
  • A letter to the editor is presented about a study on hematologic cancers following allogeneic blood-cell transplantation or bone marrow transplantation. (
  • Bone marrow and stem cell transplantation have evolved into the standard of care for many people with hematologic cancers and other blood disorders, and their use is expected to grow by 20 percent over the next decade. (
  • Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. (
  • CONCLUSIONS- These results suggest that MSC transplantation could have therapeutic effects on DPN through paracrine actions of growth factors secreted by MSCs. (
  • The improvement of the hemodynamic function as well as cardiac remodeling showed no therapeutic difference after the transplantation of both 100,000 and 500,000 stem cells. (
  • When these findings are taken together, combination therapy with MNC transplantation and AM infusion may have additional or synergetic effects on therapeutic angiogenesis for the treatment of severe peripheral vascular disease. (
  • Stem cell and bone marrow transplantation are rapidly expanding as an important therapeutic approach to many diseases. (
  • Bone marrow transplantation (BMT) is an important therapeutic option for a variety of malignant and nonmalignant disorders. (
  • Blood and Bone Marrow Transplant? (
  • For more details, see blood and marrow stem cell transplant . (
  • These films, when immersed in a special salt medium, which chemical composition is identical to human blood plasma, are able to form on its surface a special layer of calcium and phosphorus, which in natural conditions forms the main part of the bone. (
  • Learn more about our Blood and Marrow Stem Cell Transplantation Program. (
  • After being treated with high-dose anticancer drugs and/or radiation, the patient receives the harvested stem cells, which travel to the bone marrow and begin to produce new blood cells. (
  • The harvested bone marrow is then processed to remove blood and bone fragments. (
  • Myelodysplastic syndromes are a group of bone marrow stem cell disorders marked by ineffective blood cell production and low counts in the peripheral blood. (
  • For some types of blood diseases, transplantation is the standard of care. (
  • We offer the latest promising approaches in blood and bone marrow stem cell transplant. (
  • The donated tissue repopulated the marrow and restored production of the blood cells. (
  • The study, by Denis R. Burger, Ph.D., CytoDyn Chief Science Officer, and Daniel Lindner, M.D., Ph.D. of the Department of Translational Hematology and Oncology Research, The Cleveland Clinic, has been published online in the peer-reviewed journal, Biology of Blood and Marrow Transplantation . (
  • Hematopoietic Reconstitution by Transplantation of Stem Cells from Bone Marrow or Blood. (
  • When bone marrow is damaged or destroyed, it can no longer make normal blood cells and a stem cell transplant (bone marrow transplant) is required. (
  • A bone marrow transplant is the process of replacing unhealthy HSC with healthy ones in order to restart hematopoiesis, the process of generating red blood cells, white blood cells, and platelets. (
  • Our transplantation experts are closely integrated with our world-class teams of blood cancer experts and transplantation immunologists. (
  • Stem cells are taken from the patient either by bone marrow harvest or apheresis (a process of collecting peripheral blood stem cells), frozen, and then given back to the patient after intensive treatment. (
  • It is most often performed for people with diseases of the blood or bone marrow, or certain types of cancer. (
  • Dr. Thomas' work showed that bone marrow cells infused intravenously could repopulate the bone marrow and produce new blood cells. (
  • Even with the significant advances in blood and bone marrow stem cell transplant, relapse (also referred to as recurrent disease) remains the primary cause of treatment failure after both autologous and allogeneic transplantation. (
  • The optimal numbers for each cell type in the bone marrow or peripheral blood progenitor cell allograft are not known. (
  • 10-15] Transplantation with fewer than 1 × 10 6 CD34-positive cells/kg from T-cell-depleted allogeneic bone marrow and peripheral blood stem cell grafts was associated with increased relapse and treatment-related mortality. (
  • Bone marrow is the place for the production of the hematopoietic cells which differentiate in to three groups: red blood cells, white blood cells and platelets. (
  • Bone marrow is a soft, sponge-like tissue in the centre of bones where blood cells are made. (
  • Blood stem cells, which are also known as haematopoietic stem cells, can differentiate into all blood cell types, including white blood cells, red blood cells, and platelets, whereas stromal stem cells can differentiate into fat, cartilage , and bone cells. (
  • This substance increases the number of bone marrow stem cells circulating in the blood. (
  • Four weeks after transplantation, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) productions in transplanted sites, current perception threshold, nerve conduction velocity (NCV), sciatic nerve blood flow (SNBF), capillary number-to-muscle fiber ratio in soleus muscles, and sural nerve morphometry were evaluated. (
  • Most of these stem cells are found in the bone marrow (the soft inside part of the bone), although some are found in the blood (peripheral blood stem cells). (
  • At high doses the bone marrow may be damaged or destroyed, and the patient may not be able to produce the necessary blood cells. (
  • In a Bone marrow transplant (BMT), marrow containing healthy stem cells is infused to replace those damaged by the high dose therapy, so that the patient can produce blood cells again. (
  • If it is not possible to use marrow, a peripheral blood stem cell transplant (PBSCT) may be given. (
  • Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation (CancerNet) This is a detailed booklet providing information about a wide range of transplant related issues. (
  • Going home after a bone marrow or peripheral blood stem cell transplant (Royal Marsden Hospital, UK) An on-line patient booklet. (
  • Bone marrow transplantation will be mostly used in treating blood cancer, thalassemia, anaemia, etc. (
  • Then stem cells along with blood will be collected from the bone (present in the pelvic region) with the help of a needle. (
  • The department uses stem cells from various sources including bone marrow, peripheral blood, umbilical cord blood and the placenta. (
  • The laboratory's team, headed by Prof. Reuven Or, includes a number of highly respected and accomplished scientists who conduct advanced research with a focus on the immuno-biological mechanism of stem cells derived from cord blood and bone marrow. (
  • Moreover, Prof. Or serves as the Medical Director of the Volunteer Bone Marrow Bank and also as the Medical Director of the Israeli National Public Umbilical Cord Blood Bank. (
  • Bone marrow, a spongy tissue inside bones, contains stem cells that produce blood cells, including leukocytes, erythrocytes and platelets. (
  • The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. (
  • Michallet and colleagues [1] correctly assert that it is unknown how the results collected from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation regarding allogeneic bone marrow transplantation for CLL compare with those of conventional therapies. (
  • With an experienced and multidisciplinary team, we have received accreditation from the Foundation for the Accreditation of Cellular Therapy , membership of the National Pediatric Blood and Marrow Transplant Consortium and national designation as a Center of Excellence. (
  • While peripheral blood grafts may seem to be logistically easier to collect, as a bone marrow harvest requires multiple needle puncture in the pelvic bone in an operating room under anesthesia, it requires five days of growth factor injections and 6-12 hours on an apheresis machine. (
  • Approximately 20 ml bone marrow was harvested from iliac crests and 400 - 600 ml peripheral blood was collected to prepare serum for culture. (
  • All T cells are produced in the thymus from blood stem cells that originate in the bone marrow and migrate through the blood circulation to the thymus. (
  • Using a repopulation assay in mice, we show here that gene-marked, transplantable marrow cells from the plastic-nonadherent population can generate both functional osteoblasts/osteocytes and hematopoietic cells. (
  • Bone marrow cells contribute to many diverse tissues after systemic transplantation in both mice and humans ( 1 , 2 ). (
  • The influence of apoE gene dosage on serum lipid concentrations was determined by transplantation of homozygous apoE-deficient (apoE −/− ), heterozygous apoE-deficient (apoE +/− ), and wild-type (apoE +/+ ) bone marrow in homozygous apoE-deficient mice. (
  • The concentration of apoE detected in serum was found to be gene dosage dependent, being 3.52±0.30%, 1.87±0.17%, and 0% of normal in transplanted mice receiving either apoE +/+ , apoE +/− , or apoE −/− bone marrow, respectively. (
  • After 4 months on a "Western-type" diet, atherosclerosis was evidently reduced in mice transplanted with apoE +/+ bone marrow, compared with control transplanted mice. (
  • Each regimen was followed by transplantation of whole bone marrow from green fluorescent protein-expressing wild type (wt) mice. (
  • Rapid Thymic Reconstitution Following Bone Marrow Transplantation in Neonatal Mice is VEGF-Dependent. (
  • Home › About CIRM › Our Publications › Grantee publications › Rapid Thymic Reconstitution Following Bone Marrow Transplantation in Neonatal Mice is VEGF-Dependent. (
  • People are in a bit of a 'desperation' mode since their dog has already relapsed when they find us and learn about bone marrow transplantation. (
  • Our Bone Marrow and Hematopoietic Stem Cell Transplantation Program is a Center of Excellence in stem cell transplantation, as designated by the National Cancer Institute and accredited by FACT (Foundation for the Accreditation of Cellular Therapy). (
  • The goal of a bone marrow transplant is to cure many diseases and types of cancer. (
  • In this video, Sonali M. Smith, MD , director of the lymphoma program , provides an introduction to bone marrow/stem cell transplantation. (
  • The inaugural DATTA Forum meeting convened representatives of more than 80 major payers, HMOs, and medical centers to discuss the issue of autologous bone marrow transplantation for breast cancer. (
  • Bone Marrow Transplantation and Cancer Treatment An online booklet by Stephen Mahlstedt. (
  • Bone marrow transplantation is a treatment method used to treat diseases like cancer and thalassemia. (
  • Bone marrow transplantation may increase cancer resistance i. (
  • Aug. 23, 2011) Bone marrow transplantation with genetically modified cells may prolong the period of cancer-free survival, suggests a study led by Dr. Vivek Rangnekar, associate director of translational research for the Markey Cancer Center at the University of Kentucky. (
  • In a study from the United States, long-term survivors of pediatric bone marrow transplantation followed in the Bone Marrow Transplant Survivors Study were compared with survivors of childhood cancer treated without bone marrow transplant from the Childhood Cancer Survivor Study. (
  • The therapy, bone marrow transplantation, uses a dog's own stem cells to stimulate bone marrow function and immune system recovery following radiation to kill cancer cells. (
  • Such diseases require serious complex treatment and surgery and transplantation of the destroyed bone marrow in severe stages. (
  • Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. (
  • CONCLUSION: The unknown pathogenetic mechanism appears to target liver and bone marrow simultaneously, because half of the children concomitantly had low reticulocyte counts and severe liver failure. (
  • Bone marrow transplantation may also be an option for the treatment of certain non-haematological disorders. (
  • Pulmonary infiltration and bone marrow depression complicating treatment with amiodarone. (
  • Now, treatment of a number of diseases is possible through stem cell transplantation. (
  • Michael Bishop, MD, is director of stem cell transplantation and is an expert in relapse prevention and treatment. (
  • With Cox regression analysis, the use of irradiation (relative risk, 21.0), the mode of irradiation (relative risk, 7.4), and the use of steroid treatment (relative risk, 2.9) for more than 3 months after bone marrow transplantation increased the risk for cataract formation. (
  • This regimen contributed to activity that induced minimal residual disease negativity in bone marrow, which is the absence of disease after treatment. (
  • Study authors considered Gazyva an effective treatment if bone marrow minimal residual negative was 70% or more, and ineffective if this level was 55% or less. (
  • Bone marrow transplantation (BMT) 3 is increasingly used in the treatment of various malignant and nonmalignant disorders. (
  • In the late 1940s, University of Chicago researcher Dr. Leon Jacobson discovered that he could save a mouse, whose bone marrow and spleen had been destroyed with radiation, by transplanting healthy spleen tissue from another mouse. (
  • Usually for bone marrow transplantation, stem cells from bone marrow will be collected. (
  • The bone marrow can be ablated at doses that cause minimal injury to other tissues. (
  • This destroys the faulty stem cells in your bone marrow. (
  • In some cases, you can donate your own bone marrow stem cells in advance. (
  • A special bioactive coating of the material helped to increase the rate of division of bone cells by 3 times. (
  • In the experimental part of the study, the researchers compared the rate of division of osteoblastic bone cells on the surface of the modified and unmodified material. (
  • The stem cells used in BMT come from the liquid center of the bone, called the marrow. (
  • Harvested bone marrow can be combined with a preservative and frozen to keep the stem cells alive until they are needed. (
  • It also can occur if not enough stem cells are used, the new stem cells are damaged during storage, or your bone marrow is damaged after the transplant. (
  • Bone marrow is in the center of the bone and contains hematopoietic stem cells (HSC). (
  • Bone and bone marrow are closely aligned physiologic compartments, suggesting that these tissues may represent a single functional unit with a common bone marrow progenitor that gives rise to both osteoblasts and hematopoietic cells. (
  • Alternatively, the bone marrow may contain rare "marrow stem cells" with the potential to differentiate to a spectrum of tissues, possibly in response to specific environmental cues. (
  • Consistent with this idea is the observation, reported over a decade ago, that nonadherent CD34 bone marrow cells can differentiate to osteoblasts ( 12 ) and the quite recent report that murine bone marrow side population (SP) cells can engraft in bone after transplantation ( 13 ). (
  • We tested this prediction in a murine transplantation model by using gene-marked bone marrow cells and retroviral integration site-specific PCR analysis. (
  • Transduction and Transplantation of Marrow Cells. (
  • The goal of BMT is to transfuse healthy bone marrow cells into a person after his or her own unhealthy bone marrow has been treated to kill the abnormal cells. (
  • It is the stem cells that are needed in bone marrow transplant. (
  • Bone marrow cells divide frequently and are particularly sensitive to these agents. (
  • Bone marrow aspirate revealed 24% plasma cells with abnormal morphology. (
  • If the HLAs don't match, the donated bone marrow stem cells may attack the recipient's tissue. (
  • Once on the registry, only one person out of every 1,000 is ever asked to donate bone marrow stem cells. (
  • Similar procedures in humans, though more difficult, might prove helpful in isolating human stem cells and could improve the efficiency and safety of bone marrow transplantation , they add. (
  • In bone marrow tissue of bones, stem cells which are in an undifferentiated form are present. (
  • Stem cells present in the bone marrow are two kinds- Myeloid stem cells and Lymphoid stem cells. (
  • It also takes time for the bone marrow or stem cells to work properly. (
  • Bone marrow a spongy tissue inside bones contains stem cells that pr. (
  • Recent studies have shown that bone marrow stromal cells (BMSCs) transplantated into the central nervous system (CNS) can survive and differentiate into neuronal-like cells. (
  • The authors demonstrate that, in a rat model, a combination of bone marrow stromal cells and growth factor can improve the functional and histological outcome after spinal cord injury. (
  • Akiyama Y, Radtke C, Honmou O, Kocsis JD (2002) Remyelination of the spinal cord following intravenous delivery of bone marrow cells. (
  • In humans, bone marrow cells (BMCs) have usually been collected by multiple bone marrow aspirations from the iliac crest. (
  • Furthermore, gene therapy and organ transplantation have been performed using bone marrow cells (BMCs) [ 4 - 8 ]. (
  • Because the cells were immunoreactive for CD79a, CD10, and terminal deoxynucleotidyl transferase, the patient was diagnosed as having precursor B-lymphoblastic lymphoma (which is rare in adults) with bone marrow involvement. (
  • Background- Recent trials have shown that intracoronary infusion of bone marrow cells (BMCs) improves functional recovery after acute myocardial infarction. (
  • Experimental studies have shown that transplantation of bone marrow-derived cells may contribute to the regeneration of infarcted myocardium. (
  • This bone marrow film at 400X magnification demonstrates a complete absence of hemopoietic cells. (
  • EPC transplantation significantly reduced brain edema and the number of dead cells in the hematoma boundary areas. (
  • Bone marrow transplantation is the replacement of a damaged or completely destroyed bone marrow with new bone marrow cells. (
  • Within two weeks after the transplantation, the new cells find their places and start producing cells. (
  • Our data suggests that VEGF is required for the rapid phase of T cell reconstitution in new-borns but is not required for the later "maintenance" phase during adulthood when T cell production is derived from a renewable source of bone marrow stem cells. (
  • Among the different cell types evaluated to date, bone marrow stromal cells (BMSCs) have received considerable interest due to their potential neuroprotective properties. (
  • Such diseases as osteoporosis and osteomyelitis cause irreversible degenerative changes in the bone structure. (
  • Its isolation and characterization may suggest novel treatments for genetic bone diseases and bone injuries. (
  • What are some diseases that may benefit from bone marrow transplant? (
  • Bone marrow transplantation (BMT) and hematopoietic stem cell transplantation are important treatments for a variety of malignant diseases and nonmalignant disorders. (
  • Learn more about how bone marrow transplantation is evolving to help more people, treat more diseases and save more lives . (
  • High-dose busulfan is an important component of many bone marrow transplantation (BMT) preparative regimens. (
  • This type of bone marrow transplantation will be followed if a patient is treated for lymphoma, it reappears again in the patient. (
  • 73% men) ages 18 to 66 years with newly diagnosed mantle cell lymphoma who were eligible for autologous stem cell transplantation, or bone marrow transplantation. (